Am J Ind Med by Thapa, Nirmala et al.
Non-malignant respiratory disease among workers in the rubber 
manufacturing industry: A systematic review and meta-analysis
Nirmala Thapa, MPH1, Suzanne E. Tomasi, DVM, MPH, DACVPM1,2, Jean M. Cox-Ganser, 
PhD1, Randall J. Nett, MD, MPH1
1Respiratory Health Division, National Institute for Occupational Safety and Health (NIOSH), 
Centers for Disease Control and Prevention (CDC), Morgantown, West Virginia
2Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, 
Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
Abstract
Background: Non-malignant respiratory disease (NMRD) cases have occurred among rubber 
manufacturing workers. We examined exposure to rubber manufacturing emissions as a risk factor 
for NMRD.
Methods: From a systematic literature review, we identified case reports and assessed cross-
sectional and mortality studies for strength of evidence of positive association (strong, 
intermediate, non-significant positive association, none) between exposure to rubber 
manufacturing emissions and NMRD-related morbidity and mortality, and conducted two meta-
analyses.
Results: We analyzed 62 articles. We identified 11 cases of NMRD. Nine (30%) of 30 cross-
sectional studies and one (4%) of 26 mortality studies had strong evidence. The summary odds 
ratio and SMR for the cross-sectional and mortality meta-analyses were 3.83 (95% confidence 
interval [CI], 2.28–6.51) and 0.90 (95%CI, 0.82–0.99), respectively.
Conclusion: Available evidence supports rubber manufacturing emissions as a potential risk 
factor for NMRD-related morbidity. Further investigations with longer follow-up periods and 
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inclusion of short-tenured workers could further define risks for NMRD and identify prevention 
strategies.
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malignant respiratory disease; occupational asthma; occupational lung disease; rubber
1 | INTRODUCTION
Several published case reports and cross-sectional epidemiologic studies have reported the 
occurrence of upper and lower respiratory symptoms and non-malignant respiratory diseases 
(NMRD) including asthma, bronchitis, emphysema, and chronic obstructive pulmonary 
disease (COPD) among workers in the rubber manufacturing industry.1–7 An estimated 725 
000 persons are employed in the U.S. plastics and rubber manufacturing industry and 
potentially exposed to emissions released during rubber manufacturing.8
Rubber manufacturing is a complex process that includes mixing and milling, extrusion, 
molding, and finishing.9 Approximately 500 ingredients are combined to produce various 
types of rubber.5,9,10 During rubber manufacturing, workers are potentially exposed to 
feedstock materials and reaction products released in the forms of gases, vapors, dusts, 
mists, and ultrafine particles, collectively referred as rubber manufacturing emissions.11–13
Occupational exposure to rubber manufacturing emissions occurs through inhalation or skin 
contact during the manufacturing process.7,9,11,14,15 Rubber manufacturing emissions can 
contain known human carcinogens such as aromatic amines, nitrosamines, and polycyclic 
aromatic hydrocarbons (PAH), and are associated with an increased risk of cancer among 
rubber workers.5,9,16,17 However, the association between exposure to rubber manufacturing 
emissions and development of NMRD is less clear. A single animal study demonstrated 
pathologic lung lesions and significant increase in lung mast cells in guinea pigs following 
inhalation exposure to high concentration of rubber vulcanization fumes;18 indicating an 
association between exposure to rubber manufacturing emissions and NMRD.
Work-related respiratory disease is common. Approximately 17% of all adult-onset asthma 
cases and 15% of COPD cases are attributable to occupational exposures.19,20 These work-
related respiratory diseases have a substantial economic impact related to healthcare cost, 
absenteeism, and disability.21 Many of the compounds used in rubber manufacturing are 
known respiratory hazards (bronchoirritants or sensitizers) that can cause acute or chronic 
respiratory symptoms.4,5,15 However, only a small proportion of the numerous chemicals 
found in rubber manufacturing have occupational exposure limits including: Occupational 
Safety and Health Administration (OSHA) permissible exposure limits (PELs), NIOSH 
recommended exposure limits (RELs), American Conference of Governmental Industrial 
Hygienists (ACGIH®) Threshold Limit Values (TLV®s), or American Industrial Hygiene 
Association (AIHA) workplace environmental exposure limits (WEEL®s). Additionally, the 
combination of chemicals and ultrafine particles could alter the expected health effects.22
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Epidemiologic investigations focusing on the carcinogenic risk associated with rubber 
manufacturing have been well-documented.9,23,24 However, to our knowledge, a 
comprehensive literature review of NMRD-related morbidity and mortality among rubber 
manufacturing workers has not been conducted. A thorough review of existing literature is 
essential to developing a better understanding of the non-carcinogenic respiratory hazards 
associated with rubber manufacturing. The purpose of this study was to systematically 
review the published scientific literature and summarize the evidence for associations 
between occupational exposure to rubber manufacturing emissions and NMRD-related 
morbidity and mortality.
2 | MATERIALS AND METHODS
We used the steps Hempel et al recommended for conducting a systematic review of 
occupational safety and health questions.25 We conducted a search of Scopus (January 1, 
1969 to June 15, 2017), Medline (January 1, 1970 to June 15, 2017), and Embase (January 
1, 1970 to June 15, 2017),a for the purpose of identifying published studies involving 
respiratory symptoms, impaired lung function, or NMRD among rubber manufacturing 
workers.
A total of 1337 unique citations were retrieved (Figure 1). Eleven duplicates were identified 
and excluded. Additional citations were eliminated because of lack of relevancy following 
review of title (n = 1193) and abstract (n = 32) by three authors (NT, SET, and RJN). These 
citations were further classified into case reports, cross-sectional studies, or mortality 
studies. Articles describing mortality studies were excluded (n = 34) when NMRD-related 
mortality was not assessed. One article was excluded because the publication was 
unavailable. Two additional articles were included following a bibliography review of the 
included studies and review of the author’s manuscript collection. During the review 
process, the authors excluded one article describing an animal study, one article describing 
non-respiratory symptoms, two articles including non-rubber manufacturing facilities, and 
two articles describing mortality studies that did not calculate standardized mortality ratios 
[SMR] for NMRD. A total of 62 articles met the inclusion criteria of the study having an 
assessment for the presence of respiratory symptoms, impaired lung function, or NMRD 
among rubber manufacturing workers. During analysis, four articles were combined and 
analyzed as two cross-sectional studies because the authors described respiratory symptoms 
and lung function abnormalities for the same cohorts in separate publications.26–29 One 
aSearch strategy and keywords: SCOPUS: TITLE-ABS-KEY (rubber OR “ethylene propylene diene monomer” OR epdm OR 
neoprene OR polychloroprene OR elastomer* OR “styrene butadiene” OR polybutadiene) AND TITLE-ABS-KEY (“threshold limit 
value” OR employee* OR facilities OR facility OR industry* OR manufactur* OR “maximum allowable concentration” OR 
occupation* OR worker* OR workplace*) AND TITLE-ABS-KEY (airway* OR alveol* OR asthma* OR bronch* OR (bronchiolit* 
W/2 oblit*) OR chest OR respirat* OR expiratory OR fev1 OR (hypersensit* W/2 pneumon*) OR inhal* OR laryng* OR lung OR 
lungs OR pneumo* OR pulmon* OR respirato* OR spiromet*) AND LANGUAGE (english) AND PUBYEAR>1969 AND NOT 
TITLE-ABS-KEY (mouse OR mice OR murine OR rats OR swine). MEDLINE and EMBASE: TITLE-ABS-KEY (rubber OR 
“ethylene propylene diene monomer” OR epdm OR neoprene OR polychloroprene OR elastomer* OR “styrene butadiene” OR 
polybutadiene) AND TITLE-ABS-KEY (“threshold limit values” OR maximum allowable concentration* OR employee* OR worker* 
OR workplace* OR occupational OR (facility or facilities) OR (industry or industries or industrial) OR manufactur* AND TITLE-
ABS-KEY (Respiratory Tract Diseases OR Respiratory system OR Diagnostic Techniques, Respiratory System OR airway* Alveolar 
Epithelial Cells OR Macrophages, Alveolar OR Pulmonary Alveoli OR (alveolar or alveoli) OR asthma* OR bronchial OR bronchitis 
OR bronch* OR bronchiolit* adj oblit* OR thorax OR chest OR expiratory OR fev1 OR (hypersensit* adj pneumon*) OR inhalation 
OR inhal* OR laryng* OR lung* OR pneumo* OR pulmon* OR respirat* OR spiromet* AND LANGUAGE (english) and yr = 
“1970-Current” AND NOT TITLE-ABS-KEY (mouse OR mice OR murine OR rats OR swine).
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article was considered both as a case series and cross-sectional study.30 Mortality studies 
assessing the same cohort during different time periods were grouped together and assigned 
a corresponding alphabet letter (Table 4). Confidence intervals (CI) not reported in mortality 
studies were calculated using OpenEpi.31
We summarized the study findings regarding exposure to rubber manufacturing emissions, 
respiratory symptoms or signs, lung function abnormalities, and NMRD diagnoses as 
defined by the original study. Cross-sectional studies (n = 30) and mortality studies (n = 26) 
were evaluated using a grading rubric developed a priori by the authors (Table 1). Each 
cross-sectional and mortality study was assessed for evidence of association between 
exposure to rubber manufacturing emissions and NMRD-related morbidity or mortality by 
three authors (NT, SET, and RJN) and strength of association was characterized as strong, 
intermediate, non-significant positive, or no association.b
We conducted a meta-analysis to analyze the association between exposure to rubber 
manufacturing emissions and development of respiratory symptoms or NMRD for the cross-
sectional and mortality studies using a data analysis guide produced by Neyeloff et al.32 We 
modified the guide spreadsheet to account for the use of SMRs and odds ratios. 
Heterogeneity was evaluated using the I2 value described by Higgins et al.33 For the cross-
sectional meta-analysis, we included cross-sectional studies that provided odds ratios with 
confidence intervals for respiratory symptoms, NMRD diagnoses, or sufficient data to 
calculate odds ratios and confidence intervals. If more than one odds ratio was reported in a 
study, we chose a lower respiratory outcome with the highest odds ratio. Among the 30 
cross-sectional studies, six studies were included in the meta-analysis and 24 were excluded. 
For the mortality meta-analysis, we included studies that reported overall SMRs for diseases 
of the respiratory system (ICD code: 427–527) in males. Nineteen mortality studies were 
included in the meta-analysis and six studies were excluded. For both meta-analyses, each 
study’s weight was calculated by the inverse of the study variance plus the between-studies 
variance.32 In the forest plots, each study’s weight was represented as a percentage of the 
sum of the weights. The results of this study were presented at the American Thoracic 
Society 2018 International Conference.34
3 | RESULTS
3.1 | Case reports
Table 2 summarizes five articles describing 11 cases of respiratory illness occurring among 
workers exposed to rubber manufacturing emissions at five facilities located in the United 
States (n = 2), Canada (1), Korea (1), and Ethiopia (1).1,2,30,35,36,37 Ten of the cases 
occurred among males. Of the 10 cases with known age, the median age was 36.5 (range: 
21–57) years. Of the 10 cases that reported symptom onset times, the median time from first 
exposure to symptom onset was 7 weeks (range: 2 weeks-4 years). Five of the 11 workers 
with respiratory illness used tobacco. Among these 11 cases, symptoms and conditions 
included rhinorrhea (n = 1), nasal congestion (1), sinusitis (1), rhinitis (1), hoarseness (2), 
chronic laryngitis (1), breathlessness (1), dyspnea (6), wheezing (4), chest congestion (1), 
bAssigned to studies that did not meet the criteria for the other categories of strength of association.
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cough (4), sputum production (2), chest pain (1), chest tightness (2), early pneumonia (1), 
pneumonic infiltrates (1), pneumonitis (1), interstitial fibrosis (1), bilateral interstitial 
infiltrates (1), acute respiratory distress (1),asthma symptoms (1), 
nasolaryngotracheobronchitis (1), and chronic bronchitis (2). One case of occupational 
asthma and one case of acute eosinophilic pneumonia were also identified. Work roles 
included press operators in the thermo-injection process (n = 5), cushion mill operator (1), 
working in the heat press process (1), tire curing process (1), passenger tire builder (1), and 
calender operators (2). Six workers had respiratory conditions and eosinophilia; the 
eosinophil count for five workers was not reported. Nine workers were hospitalized and no 
workers died.
Bascom et al described five workers who worked as press operators in the thermo-injection 
process at a single facility.1 The workers were exposed to heated chloroprene-based rubber 
that was injected into the metal molds. The onset of respiratory symptoms for all workers 
occurred 2–6 weeks after an increase in production that resulted in an increase in rubber 
manufacturing emissions. Two and five workers experienced upper and lower respiratory 
symptoms, respectively. Two had abnormal spirometry (obstruction = 1; restriction = 1) and 
one had a decrease in diffusing capacity. Eosinophilia was observed for each press operator. 
All five workers returned to work after treatment and were transferred to other work areas 
within the facility.
An article by Kato and Leki reported one case in a 31-year-old male who had the task of 
pouring raw materials into molds and a heat press.35 His symptoms began two months after 
exposure and included dyspnea and fever. He also had bilateral diffuse infiltrates on chest 
radiographs and eosinophilia. He was diagnosed with acute eosinophilic pneumonia and 
hospitalized. He was discharged following treatment with oral steroids, at which time he 
returned to work with no subsequent recurrence of acute eosinophilic pneumonia.
The Korean Occupational Safety and Health Research Institute described a tire curing 
machine operator in his 30s who developed asthma symptoms after four years of work in a 
tire manufacturing facility.36,37 With exposure to rubber manufacturing emissions that 
ranged from 0.18 to 0.80 mg/m3, the worker’s average peak expiratory flow decreased from 
417.1 L/min on a rest day to 361.7 L/min on working day.
Another article by Tarlo reported a case in a 55-year-old male who worked at a rubber tire 
manufacturing facility as a cushion mill operator where his task was to apply hot rubber 
coating to rubber strips.2 His symptoms of rhinitis started one year after exposure to a newly 
introduced chemical (crude tall oil, heated to 100°C) at the workplace. Three months later, 
he was hospitalized for asthma. While away from work, his symptoms resolved and lung 
function results were normal. Following his return to work, he experienced a reoccurrence of 
respiratory symptoms and a decline in peak expiratory flows. A single-patient blinded 
specific inhalation challenge was conducted using tall oil resin, with molasses as a control 
substance. Lung function remained stable following an inhalation challenge with molasses. 
However, following an inhalation challenge to tall oil resin for 65 min he became dyspneic 
with a 60% decrease in forced expiratory volume in one second (FEV1), resulting in a 
diagnosis of occupational asthma.
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One cross-sectional study by doPico et al. described three case reports that occurred among 
one passenger tire builder and two calender operators.30 All three workers had worked in the 
plant for an average of 26 years (range: 15–34 years) and each of them developed upper and 
lower respiratory symptoms 1–2 months following exposure to the newly introduced 
thermosetting resin at the workplace. Two of the workers returned to work despite having a 
chronic productive cough, intermittent wheezing, mild dyspnea, and 
nasolaryngotracheobronchitis; one calender operator was unable to continue working 
because of chronic laryngitis and severe bronchitis.
3.2 | Cross-sectional studies
Table 3 summarizes 32 articles describing 30 cross-sectional studies evaluating the presence 
of respiratory symptoms and NMRD among workers exposed to rubber manufacturing 
emisssions.3–7,10–12,14,15,21,26–30,38–53 Occupational cohorts (n = 10 896 workers in total) 
across studies varied from 34 to 1820 workers, and included facilities from the United States 
(n = 14), Sweden (6), India (3), Iran (3), Italy (1), Netherlands (1), Poland (1), and Turkey 
(1). Nineteen studies evaluated both respiratory symptoms/diagnoses and spirometry 
measurements, eight respiratory symptoms/diagnoses only, and three spirometry 
measurements only.
All of the 30 cross-sectional studies had non-significant positive or higher evidence of 
association between exposure to rubber manufacturing emissions and respiratory morbidity. 
Nine (30%) studies had strong evidence, nine (30%) intermediate, and 12 (40%) non-
significant positive association. Compared with controls, exposed workers in 15 (52%), 11 
(38%), and 3 (10%) cross-sectional studies had a statistically significant higher prevalence 
of respiratory symptoms, airflow limitation, or NMRD, respectively. Respiratory symptoms 
reported among the exposed workers included nosebleed, nasal congestion, shortness of 
breath, cough, sputum production, dyspnea, wheeze, chest tightness, chest irritation, and 
chest pain. NMRD diagnoses included sinusitis, pharyngitis, chronic bronchitis, 
emphysema, COPD, and asthma. Twenty-two studies conducted spirometry measurements; 
of these, reductions were reported in FEV1 (n = 6), forced vital capacity (FVC) (6), vital 
capacity (VC) (1), FEV1/FVC (8), forced expiratory flow (FEF) at 75% of FVC (1), FEF at 
50% of FVC (1), and FEF at 25% of FVC (1).
Workers included in the cross-sectional studies had known exposures to rubber 
manufacturing emissions that included suspended dusts, organic and inorganic vapors, 
respirable and inhalable talc dust, napthalene-diisocyanate (NDI) fumes, respirable 
particulate matter, polycyclic aromatic hydrocarbons (including benzo(a)pyrene), sulphates, 
nitrates, thermosetting resin, or carbon black. Twenty-six (87%) of the cross-sectional 
studies assessed for tobacco use among workers; 19 (63%) of those studies reported 
respiratory symptoms or lung function associated with smoking. For example, one study 
described prevalence of lung impairment among exposed non-smokers (odds ratio = 3.45, 
95%CI, 1.76–9.50), exposed smokers (12.12, 3.35–37.87), and non-exposed smokers (3.48, 
1.42–8.33) compared with non-exposed non-smokers.14
For the meta-analysis of cross-sectional studies, odds ratios with confidence intervals from 
six cross-sectional studies were analyzed using a random effects model (Figure 2). We 
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selected the random effects model because of the moderate-to-high I2 value (67.6%)33 and 
the perceived heterogeneity observed during the formal review. The overall odds ratio for the 
cross-sectional meta-analysis was 3.83 (95% CI, 2.28–6.51).
3.3 | Mortality studies
Table 4 summarizes 26 articles describing 26 mortality studies of 14 occupational cohorts 
involving 270,408 workers (range: 327–40 867).16,17,23,54–76 These mortality studies 
included workers from facilities in the United States (n = 13), Germany (4), United 
Kingdom (4), Italy (2), Sweden (2), and one study included facilities from five European 
countries (Germany, Italy, Poland, Sweden, and United Kingdom).
The primary focus of these mortality studies was cancer. For the purpose of our review, 
NMRD-related mortality was caused by diseases of the respiratory system other than cancer 
including asthma, bronchitis, chronic airway obstruction, COPD, emphysema, and 
pneumonia. Median required work tenure was one year (range: 1 day-5 years). Twenty 
(77%) studies excluded workers with work tenure <1 year and therefore were not designed 
to assess the relationship between mortality from NMRD and these short-term exposures.
Of the 26 studies addressing NMRD mortality, one (4%) had strong, four (15%) had 
intermediate, 10 (39%) had non-significant positive association, and 11 (42%) had no 
evidence of association between exposure to rubber manufacturing emissions and NMRD-
related mortality. A mortality study among curing workers, which have a higher exposure to 
curing fumes compared with other workers,9 had strong association for NMRD-related 
mortality; the SMR for pneumonia was 2.2 (95%CI, 1.37–3.38).61
Among the four studies demonstrating intermediate association, one reported elevated 
mortality for COPD (SMR = 1.22, 95%CI, 1.01–1.46) among retired workers in the German 
rubber industry.16 Another identified elevated mortality among retired U.S. male rubber 
manufacturing workers aged 40–64 years from bronchitis, emphysema, and asthma (SMR = 
1.84, 95%CI, 1.43–2.40) and other respiratory diseases (SMR = 3.09, 95%CI, 1.8–5.08).55 
A third study among tire manufacturing workers with different work tenures (range: <6 
months-10 years) described various NMRD-related mortalities among workers with tenure 
<6 months, 6 month-2.5 years, >2.5–10 years, and >10 years (SMR = 2.06, 95%CI, 1.36–
3.00; 1.92, 1.23–2.85; 1.23, 0.71–1.96 and, 0.59, 0.27–1.12, respectively).69 Mortality 
related to NMRD and chronic airway obstruction among workers with 10 years latency was 
also elevated (SMR = 1.46, 95%CI, 1.15–1.83; 1.67, 1.17–2.31, respectively). Finally, a 
fourth study reported mortality for bronchitis, emphysema, and asthma (SMR = 1.82, 
95%CI, 1.06–2.94) among workers in different sectors (sponge rubber, rubber with plastic, 
crepe rubber, etc.) of the rubber and cable making industry.76
For the meta-analysis of mortality studies, SMRs with confidence intervals from 19 
mortality studies were analyzed for the association of rubber manufacturing emissions and 
NMRD-related mortality (Figure 3). Because I2 was moderate-to-high (63.2%) and a high 
heterogeneity was perceived during the formal review,33 the random effect model was used 
for the meta-analysis. The overall SMR for the mortality studies meta-analysis was 0.90 
(95%CI, 0.82–0.99).
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4 | DISCUSSION
This systematic review identified some evidence that exposure to rubber manufacturing 
emissions is positively associated with NMRD. Available evidence included: (1) 11 case 
reports of respiratory conditions occurring among workers in rubber manufacturing 
facilities, including one case report of occupational asthma that included a positive specific 
inhalation challenge and one case of acute eosinophilic pneumonia; (2) all 30 cross-sectional 
studies provided at least non-significant positive association between exposure to rubber 
manufacturing emissions and development of respiratory symptoms, lung function 
abnormalities, or NMRD, including nine studies that had strong evidence of association; and 
(3) the meta-analysis among the six cross-sectional studies that calculated an odds ratio 
indicated a significant positive association between rubber manufacturing emissions and 
respiratory symptoms or NMRD. Although 15 of 26 mortality studies had at least non-
significant positive association between exposure to rubber manufacturing emissions and 
NMRD-related mortality, the mortality study meta-analysis found no association. However, 
one mortality study did indicate strong evidence of association between rubber 
manufacturing emissions and NMRD-related mortality.
The majority of the cross-sectional and mortality studies included in this review did not 
conduct a comprehensive exposure analysis. Among the cross-sectional studies, only nine 
discussed exposure to specific chemicals (Napthalene-diisocyanate, talc dust, 
hexamethylenetetramine-resorcinol resin, benzo(a)pyrene, carbon disulfide, and carbon 
black dust) while the other 21 described general rubber manufacturing emissions exposure. 
Rubber manufacturing workers are exposed to a multitude of natural or anthropogenic 
chemicals and high concentrations of ultrafine particles through inhalation routes.9 Evidence 
has indicated that mixing natural or anthropogenic chemicals with combustion-produced fine 
and ultrafine particles might increase transfer of chemicals into the respiratory cells; thus, 
increasing respiratory morbidity and mortality.22,77 The complexity of rubber manufacturing 
exposures makes completing an accurate exposure analysis and determining the role rubber 
manufacturing emissions exposure plays in the development of NMRD difficult.9 Because of 
the challenges in attributing specific exposures to health outcomes, animal studies of rubber 
manufacturing emissions could contribute to a better understanding of the potential 
respiratory toxicity that occurs from working in rubber manufacturing.
Work-related asthma is characterized by asthma symptoms that occur in a previously healthy 
worker (occupational asthma) or a worker previously diagnosed with asthma whose 
symptoms are made worse by the workplace (work-exacerbated asthma).78 There are over 
300 known respiratory irritants and sensitizers that can lead to the development of work-
related asthma and many are found in dusts, fumes, and vapors from rubber manufacturing.
4,5,15,79,80
 Several studies and case reports identified during this systematic review described 
cases of work-related asthma including a confirmed case of occupational asthma diagnosed 
following a positive specific inhalation challenge.2 Additionally, six cross-sectional studies 
reported a higher prevalence of asthma, a significantly higher number of respiratory 
symptoms, and a reduction in lung function among workers with higher exposures to rubber 
manufacturing emissions compared with controls.7,15,21,26,40,41 Furthermore, four mortality 
studies that were focused on malignant disease-related mortality reported SMRs for asthma, 
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bronchitis, and emphysema including two with statistically significant SMRs55,76 and two 
with a non-significant positive association.54,73 Finally, another mortality study reported a 
non-significant positive SMR for asthma.63 Because of the possibility of work-related 
asthma occurring among rubber manufacturing workers, symptom surveillance, and 
improving clinician awareness of work-related asthma risks among rubber manufacturing 
workers might help identify asthma caused by rubber manufacturing emissions sooner.
Six of the 11 case reports included in this review described workers from two rubber 
manufacturing facilities who had respiratory conditions and eosinophilia.1,35 Eosinophilia 
with airway inflammation occurs in a number of respiratory conditions including allergic 
rhinitis, asthma, bronchitis, and COPD.81 Allergic airway sensitivity has been associated 
with inhalational exposure to combustion products,82,83 and occupational exposures have 
been associated with eosinophil production.81 A recent study among professional firefighters 
who had chronic and prolonged exposure to smoke and numerous ultrafine particulates 
reported statistically significantly higher percentage of eosinophils on induced sputum and 
bronchoalveolar lavage fluid testing compared with healthy subjects or firefighter trainees, 
and demonstrated a significant correlation between the percentage of sputum eosinophils 
and years of service.84 Identification of eosinophilic asthma versus non-eosinophilic asthma 
has important implications for identification of potential causes and for selecting appropriate 
treatments.85 Although sputum eosinophilia is the gold standard of diagnosis for 
eosinophilic asthma, persons with blood eosinophil counts of more than 400 cells/μL can be 
expected to have increased sputum eosinophils.85 Therefore, the use of blood eosinophil 
counts among rubber manufacturing workers who experience respiratory symptoms and the 
use of non-invasive biomarkers, such as fraction of exhaled nitric oxide (FeNO) that can 
predict the presence of sputum eosinophilia, can help identify cases of eosinophilic asthma.
86
The cross-sectional studies included in this review likely underestimated the prevalence of 
NMRD-related morbidity. Cross-sectional studies are subject to healthy worker bias because 
ill workers leave the workplace resulting in a healthier workforce.87 Even so, each of the 30 
cross-sectional studies had at least a non-significant positive association between exposure 
to rubber manufacturing emissions and NMRD-related morbidity. In addition, a meta-
analysis of six cross-sectional studies demonstrated a significant positive association of 
rubber manufacturing emissions and respiratory symptoms or NMRD. Among the 30 cross-
sectional studies, 22 incorporated only spirometry to assess lung function changes among 
rubber manufacturing workers. Although spirometry is commonly used to identify work-
related NMRD, baseline lung function testing that includes spirometry combined with other 
non-traditional testing methods such as impulse oscillometry or FeNO might improve 
NMRD testing sensitivity. Spirometry, as a single lung function test, has a poor sensitivity 
for work-related asthma.88 Identifying work-related asthma in a cross-sectional study 
includes establishing a relationship between symptoms and work through a medical 
questionnaire and lung function testing.89,90 To improve detection of asthma and other 
work-related lung conditions among rubber manufacturing workers during future cross-
sectional studies, consideration should be given to completion of comprehensive studies that 
include medical questionnaire, spirometry, and other non-traditional testing methods that can 
aid in the identification of asthma and other airway diseases.86,91,92 Additionally, repeating 
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these comprehensive studies could help identify rubber manufacturing workers with 
excessive declines in lung function at earlier stages of NMRD.93,94
Although 15 of the 26 mortality studies indicated at least a non-significant positive 
association, the meta-analysis for the mortality studies demonstrated no association between 
rubber manufacturing emissions and NMRD-related mortality. However, the mortality 
studies included in this review were likely limited in their ability to detect work-related 
NMRD-related mortality for multiple reasons. First, the mortality studies were designed to 
detect cancer-related mortality. Consequently, the studies assessed cumulative exposures 
over long periods and the majority of studies excluded short-tenured workers, which likely 
limited the identification of respiratory mortality associated with short-term higher 
exposures to rubber manufacturing emissions. For example, the case reports included in this 
study had a median time from exposure to symptom onset of seven weeks. Eight of the 11 
mortality studies with no evidence of association between exposure to rubber manufacturing 
emissions and NMRD-related mortality excluded workers with tenure <1 year. One study of 
tire manufacturing workers demonstrated a higher mortality for diseases of the respiratory 
system among workers with a tenure <6 months (SMR = 2.06, 95%CI, 1.36–3.00) compared 
with workers with tenure 6 months-2.5 years tenure (SMR = 1.92, 95%CI, 1.23–2.85), >2.5–
10 years tenure (SMR = 1.23, 95%CI, 0.71–1.96), and >10 years tenure (SMR = 0.59, 
95%CI, 0.27–1.12).69 Second, death certificates are not sensitive for detecting occupational 
lung diseases,95 and classification of causes of death reported in death certificates is often 
inaccurate with frequent discordance with clinical and autopsy information.96 Third, work-
related COPD mortalities might be falsely attributed to tobacco-related mortalities because 
of the strong causal association with tobacco smoking and the late onset of disease.97 To 
improve detection of work-related respiratory disease mortality, future mortality studies of 
rubber manufacturing worker cohorts should include: NMRD cause of death codes, longer 
follow-up periods, short-tenured workers, and methods to adjust for confounding of tobacco 
use such as standardized rate ratios.98
This study is subject to several limitations. First, systematic reviews are subject to 
publication bias of the articles reviewed, which might bias the findings towards a positive 
association between exposure to rubber manufacturing emissions and development of 
NMRD-related morbidity or mortality. However, in general, the mortality studies were 
designed to detect cancer-related mortality and negative findings of NMRD-related mortality 
would not have precluded their publication. Second, the mortality studies did not assess for a 
history of tobacco use. Therefore, if the rubber manufacturing workers used tobacco at a 
higher rate than the general population, the studies might be skewed toward a positive 
association between employment at a rubber manufacturing facility and NMRD-related 
mortality. Third, the majority of cross-sectional and mortality studies were lacking detailed 
exposure information, which limited the ability to compare exposures across studies. Fourth, 
this review included rubber manufacturing emissions studies from over a span of 42 years. 
During this period, substantial changes in rubber manufacturing work practices have 
occurred,13 which potentially affected the comparability or contemporary relevance of some 
of the results and conclusions. Finally, our review was restricted to published studies written 
in the English language, which might have underestimated the occurrence of NMRD among 
rubber workers and the systematic review results.
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In summary, a systematic review of available case reports, cross-sectional studies, and 
mortality studies provided some evidence that working in rubber manufacturing is 
potentially associated with NMRD-related morbidity and mortality, with more evidence for 
association with morbidity. Conducting detailed exposure assessments during cross-sectional 
studies that also include traditional (eg, spirometry) and non-traditional testing modalities 
(eg, FeNO and impulse oscillometry), and associating specific exposures to health outcomes, 
could help to further describe the association between exposure to rubber manufacturing 
emissions and respiratory morbidity. Furthermore, future studies assessing mortality among 
rubber manufacturing workers should include short-tenured workers and use statistical 
methods that adjust for confounding from tobacco use. Finally, conducting animal studies 
involving individual and mixed exposures of the predominant chemicals used in rubber 
manufacturing could help public health professionals better understand the potential 
respiratory toxicity associated with rubber manufacturing.
ACKNOWLEDGMENTS
The authors thank William Thomas, CDC for assistance with the literature search, Dr David Blackley, NIOSH and 
Dr George R. Grimes, NIOSH for their technical reviews, and Dr Kristin Cummings, NIOSH for her medical 
review.
REFERENCES
1. Bascom R, Fisher JF, Thomas RJ, Yang WN, Baser ME, Baker JH. Eosinophilia, respiratory 
symptoms and pulmonary infiltrates in rubber workers. Chest 1988;93:154–158. [PubMed: 
3335147] 
2. Tarlo SM. Occupational asthma induced by tall oil in the rubber tyre industry. Clin Exp Allergy 
1992;22:99–101. [PubMed: 1551039] 
3. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary 
disease and employment by industry and occupation in the US population: a study of data from the 
Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002;156:738–746. 
[PubMed: 12370162] 
4. Akca ASD, Demircan N, Kart L, Altin R. Evaluation of respiratory symptoms in workers of a 
rubber factory. Eur J Gen Med 2011;8: 302–307.
5. Governa M, Comai M, Valentino M, Antonicelli L, Rinaldi F, Pisani E. Ventilatory function in 
rubber processing workers: acute changes over the workshift. Br J Ind Med 1987;44:83–89. 
[PubMed: 3814549] 
6. Jonsson LS, Broberg K, Axmon A, Jonsson BAG, Littorin M. Symptoms and immunologic markers 
among vulcanization workers in rubber industries in southern Sweden. Scand J Work Environ 
Health 2007;33:272–279. [PubMed: 17717619] 
7. Meijer E, Heederik D, Kromhout H. Pulmonary effects of inhaled dust and fumes: exposure-
response study in rubber workers. Am J Ind Med 1998;33:16–23. [PubMed: 9408525] 
8. U.S. Bureau of Labor Statistics (BLS). About the Plastics and Rubber Products Manufacturing 
subsector 2018; https://www.bls.gov/iag/tgs/iag326.htm. Accessed April 09, 2018.
9. International Agency for Research on Cancer. IARC Working Group on the Evaluation of 
Carcinogenic Risk to Humans. Occupational Exposures in the Rubber Manufacturing Industry 
2012; 100 F:https://www.ncbi.nlm.nih.gov/books/NBK304412/. Accessed August 10, 2017.
10. Gupta P, Banerjee DK, Bhargava SK, Kaul R, Shankara VR. Effect of pollutants on airway 
resistance in rubber factory workers. Indoor Built Environ 1993a;2:105–110.
11. McMichael AJ, Gerber WS, Gamble JF, Lednar WM. Chronic respiratory symptoms and job type 
within the rubber industry. J Occup Med 1976;18:611–617. [PubMed: 966093] 
Thapa et al. Page 11
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Jonsson LS, Jonsson BA, Axmon A, Littorin M, Broberg K. Influence of glutathione-related genes 
on symptoms and immunologic markers among vulcanization workers in the southern Sweden 
rubber industries. Int Arch Occup Environ Health 2008a;81: 913–919. [PubMed: 18066575] 
13. Forrest M The composition and nature of vulcanisation fumes in the rubber industry-A technical 
review. Prog Rubber Plast Re 2015;31:219–264.
14. Attarchi M, Dehghan F, Afrasyabi M, Sadeghi Z, Mohammadi S. Combined effect of cigarette 
smoking and occupational exposures on lung function: a cross-sectional study of rubber industry 
workers. Workplace Health Saf 2013;61:213–220. [PubMed: 23650896] 
15. Zuskin E, Mustajbegovic J, Schachter EN, Doko-Jelinic J, Budak A. Longitudinal study of 
respiratory findings in rubber workers. Am J Ind Med 1996;30:171–179. [PubMed: 8844047] 
16. Weiland SK, Mundt KA, Keil U, et al. Cancer mortality among workers in the German rubber 
industry: 1981–91. Occup Environ Med 1996;53:289–298. [PubMed: 8673175] 
17. Vlaanderen J, Taeger D, Wellman J, Keil U, Schuz J, Straif K. Extended cancer mortality follow-up 
of a German rubber industry cohort. J Occup Environ Med 2013;55:966–972. [PubMed: 
23887703] 
18. Rydzynski K, Domanska A, Czerczak S, Krysiak B. The effect of subchronic exposure to the 
rubber vulcanization fumes on guinea pig lungs. Pol J Occup Med 1990;3:43–50. [PubMed: 
2132935] 
19. Torén K, Blanc PD. Asthma caused by occupational exposures is common - A systematic analysis 
of estimates of the population-attributable fraction. BMC Pulm Med 2009;9:7–7. [PubMed: 
19178702] 
20. Blanc PD. Occupation and COPD: a brief review. J Asthma 2012;49: 2–4. [PubMed: 21895566] 
21. Lednar WM, Tyroler HA, McMichael AJ, Shy CM. The occupational determinants of chronic 
disabling pulmonary disease in rubber workers. J Occup Med 1977;19:263–268. [PubMed: 
758090] 
22. Penn A, Murphy G, Barker S, Henk W, Penn L. Combustion-Derived ultrafine particles transport 
organic toxicants to target respiratory cells. Environ Health Perspect 2005;113:956–963. [PubMed: 
16079063] 
23. Straif K, Keil U, Taeger D, et al. Exposure to nitrosamines, carbon black, asbestos, and talc and 
mortality from stomach, lung, and laryngeal cancer in a cohort of rubber workers. Am J Epidemiol 
2000;152: 297–306. [PubMed: 10968374] 
24. Kogevinas M, Sala M, Boffetta P, Kazerouni N, Kromhout H, Hoar-Zahm S. Cancer risk in the 
rubber industry: a review of the recent epidemiological evidence. Occup Environ Med 1998;55:1–
12. [PubMed: 9536156] 
25. Hempel S, Xenakis L, Danz M. Systematic reviews for occupational safety and health questions 
Santa Monica, CA: RAND Corporation 2016; 1–88. Available at: https://www.rand.org/
content/dam/rand/pubs/research_reports/RR1400/RR1463/RAND_RR1463.pdf. Accessed August 
18, 2017.
26. Fine LJ, Peters JM. Respiratory morbidity in rubber workers: I. Prevalence of respiratory 
symptoms and disease in curing workers. Arch Environ Health 1976a;31:5–9. [PubMed: 1244807] 
27. Fine LJ, Peters JM. Respiratory morbidity in rubber workers: II. Pulmonary function in curing 
workers. Arch Environ Health 1976b;31: 10–14. [PubMed: 1244803] 
28. Weeks JL, Peters JM, Monson RR. Screening for occupational health hazards in the rubber 
industry. Part I. Am J Ind Med 1981a;2:125–141. [PubMed: 7349039] 
29. Weeks JL, Peters JM, Monson RR. Screening for occupational health hazards in the rubber 
industry. Part II: health hazards in the curing department. Am J Ind Med 1981b;2:143–151. 
[PubMed: 7349040] 
30. doPico GA, Rankin J, Chosy LW, et al. Respiratory tract disease from thermosetting resins. Study 
of an outbreak in rubber tire workers. Ann Intern Med 1975;83:177–184. [PubMed: 1147451] 
31. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public 
Health 2013; https://www.openepi.com/SMR/SMR.htm. Accessed August 30, 2017.
32. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel 
spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes 2012;5:52–
52. [PubMed: 22264277] 
Thapa et al. Page 12
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 
(Clinical Research ed) 2003;327: 557–560.
34. Thapa N, Tomasi SE, Cox-Ganser JM, Nett RJ. Non-malignant respiratory disease among rubber 
workers. Am J Respir Crit Care Med 2018;197:A2582.
35. Kato T, Ieki R. A case of acute eosinophilic pneumonia associated with heated rubber fume 
exposure. Allergol Int 2005;54:491–494.
36. Lee JS, Kwak HS, Choi BS, Park SY. A case of occupational asthma in a plastic injection process 
worker. Ann Occup Environ Med 2013;25:25. [PubMed: 24472161] 
37. >Occupational Safety and Health Research Institute. Occupational disease casebook Republic of 
Korea Korea Occupational Safety and Health Research Agency; 2013.
38. Alexandersson R, Gustafsson P, Hedenstierna G, Rosen G. Exposure to naphthalene-diisocyanate 
in a rubber plant: symptoms and lung function. Arch Environ Health 1986;41:85–89. [PubMed: 
3718007] 
39. Bascom R, Baser ME, Thomas RJ, Fisher JF, Yang WN, Baker JH. Elevated serum IgE, 
eosinophilia, and lung function in rubber workers. Arch Environ Health 1990;45:15–19. [PubMed: 
2317085] 
40. Fine LJ, Peters JM. Studies of respiratory morbidity in rubber workers: Part III. Respiratory 
morbidity in processing workers. Arch Environ Health 1976c;31:136–140. [PubMed: 1275557] 
41. Fine LJ, Peters JM, Burgess WA, Di Berardinis LJ. Studies of respiratory morbidity in rubber 
workers. Part IV. Respiratory morbidity in talc workers. Arch Environ Health 1976;31:195–200. 
[PubMed: 942261] 
42. Gamble JF, McMichael AJ, Williams T, Battigelli M. Respiratory function and symptoms: an 
environmental-epidemiological study of rubber workers exposed to a phenolformaldehyde type 
resin. Am Ind Hyg Assoc J 1976a;37:499–513. [PubMed: 1008033] 
43. Gupta P, Banerjee DK, Bhargava SK, Kaul R, Ravi Shankar VS. Prevalence of impaired lung 
function in rubber manufacturing factory workers exposed to benzo(a)pyrene and respirable 
particulate matter. Indoor Built Environ 1993b;2:26–31.
44. Gupta P, Banerjee DK, Bhargava SK, Kaul R, Shanker VR. Abnormal pattern of lung functions in 
rubber factory workers. J Indian Med Assoc 1994;92:260–263. [PubMed: 7963614] 
45. Jonsson LS, Broberg K, Axmon A, Bergendorf U, Littorin M, Jonsson BAG. Levels of 1-
hydroxypyrene, symptoms and immunologic markers in vulcanization workers in the southern 
Sweden rubber industries. Int Arch Occup Environ Health 2008b;82:131–137. [PubMed: 
18425528] 
46. Jonsson LS, Lindh CH, Bergendorf U, Axmon A, Littorin M, Jonsson BA. N-nitrosamines in the 
southern Swedish rubber industries - exposure, health effects, and immunologic markers. Scand J 
Work Environ Health 2009;35:203–211. [PubMed: 19404559] 
47. Jonsson LS, Littorin M, Axmon A, Jonsson BA, Broberg K. Lung function in relation to 2-
thiothiazolidine-4-carboxylic acid and genetic effect modification among rubber workers in 
Sweden. J Occup Environ Med 2008c;50:1006–1012. [PubMed: 18784548] 
48. Neghab M, Mohraz MH, Hassanzadeh J. Symptoms of respiratory disease and lung functional 
impairment associated with occupational inhalation exposure to carbon black dust. J Occup Health 
2011;53: 432–438. [PubMed: 21996929] 
49. Neghab M, Rahimi E, Emad A, Rajaeei Fard AR. An epidemiological study of talc-related 
respiratory morbidity among employees of a rubber industry in Shiraz-Iran. Int Arch Occup 
Environ Health 2007;80: 539–546. [PubMed: 17165065] 
50. Sparks PJ, Smith TJ, Fine LJ, Treitman RD, Spiegelman DL. Respiratory morbidity among 
processing and mill workers. A cross-sectional survey in three tire-manufacturing plants. J Occup 
Med 1982;24: 690–695. [PubMed: 7131111] 
51. Thomas RJ, Bascom R, Yang WN, et al. Peripheral eosinophilia and respiratory symptoms in 
rubber injection press operators: a case-control study. Am J Ind Med 1986;9:551–559. [PubMed: 
3740072] 
52. Szubert Z, Szeszenia-Dabrowska N, Sobala W. Sickness absence in a rubber plant in Poland. Int J 
Occup Med Environ Health 1998;11: 179–188. [PubMed: 9753897] 
Thapa et al. Page 13
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
53. Gamble J, Liu S, McMichael AJ, Waxweiler RJ. Effect of occupational and nonoccupational 
factors on the respiratory system of vinyl chloride and other workers. J Occup Med 1976b;18:659–
670. [PubMed: 966081] 
54. Andjelkovich D, Taulbee J, Blum S. Mortality of female workers in rubber manufacturing plant. J 
Occup Med 1978;20:409–413. [PubMed: 671118] 
55. Andjelkovich D, Taulbee J, Symons M. Mortality experience of a cohort of rubber workers, 1964–
1973. J Occup Med 1976;18: 387–394.
56. McMichael AJ, Spirtas R, Kupper LL. An epidemiologic study of mortality within a cohort of 
rubber workers, 1964–72. J Occup Med 1974;16:458–464. [PubMed: 4842655] 
57. Beall C, Corn M, Cheng H, Matthews R, Delzell E. Mortality and cancer incidence among tire 
manufacturing workers hired in or after 1962. J Occup Environ Med 2007;49:680–690. [PubMed: 
17563612] 
58. Delzell E, Monson RR. Mortality among rubber workers: V. Processing workers. J Occup Med 
1982a;24:539–545. [PubMed: 7119914] 
59. Delzell E, Monson RR. Mortality among rubber workers: VI. Men with potential exposure to 
acrylonitrile. J Occup Med 1982b;24:767–769. [PubMed: 7143123] 
60. Delzell E, Monson RR. Mortality among rubber workers: VII. Aerospace workers. Am J Ind Med 
1984;6:265–271. [PubMed: 6496477] 
61. Delzell E, Monson RR. Mortality among rubber workers: IX. Curing workers. Am J Ind Med 
1985a;8:537–544. [PubMed: 4073051] 
62. Delzell E, Monson RR. Mortality among rubber workers: X. Reclaim workers. Am J Ind Med 
1985b;7:307–313. [PubMed: 3993647] 
63. Monson RR, Nakano KK. Mortality among rubber workers. I. White male union employees in 
Akron, Ohio. Am J Epidemiol 1976;103: 284–296. [PubMed: 1258857] 
64. Dost A, Straughan J, Sorahan T. A cohort mortality and cancer incidence survey of recent entrants 
(1982–91) to the UK rubber industry: findings for 1983–2004. Occup Med (Oxf) 2007;57: 186–
190. [PubMed: 17229717] 
65. Straughan JK, Sorahan T. Cohort mortality and cancer incidence survey of recent entrants (1982–
91) to the United Kingdom rubber industry: preliminary findings. Occup Environ Med 
2000;57:574–576. [PubMed: 10896966] 
66. Pira E, Pelucchi C, Romano C, Manzari M, Negri E, La Vecchia C. Mortality from cancer and 
other causes in an Italian cohort of male rubber tire workers. J Occup Environ Med 2012;54:345–
349. [PubMed: 22361990] 
67. Sathiakumar N, Delzell E, Hovinga M, et al. Mortality from cancer and other causes of death 
among synthetic rubber workers. Occup Environ Med 1998;55:230–235. [PubMed: 9624276] 
68. Sathiakumar N, Delzell E. A follow-up study of mortality among women in the North American 
synthetic rubber industry. J Occup Environ Med 2009;51:1314–1325. [PubMed: 19858743] 
69. Wingren G Mortality in a Swedish rubber tire manufacturing plant: occupational risks or an 
“unhealthy worker” effect? Am J Ind Med 2006;49:617–623. [PubMed: 16691613] 
70. Delzell E, Louik C, Lewis J, Monson RR. Mortality and cancer morbidity among workers in the 
rubber tire industry. Am J Ind Med 1981;2: 209–216. [PubMed: 7345925] 
71. Boniol M, Koechlin A, Swiatkowska B, et al. Cancer mortality in cohorts of workers in the 
European rubber manufacturing industry first employed since 1975. Ann Oncol 2016;27:933–941. 
[PubMed: 26884594] 
72. Mirabelli D, Cacciatore AM, Ferrante D, Amendola P, Vermeulen R, Merletti F. Cohort study of 
workers employed in an Italian tire manufacturing plant, 1962–2004. Cancer Causes Control 
2012;23: 2023–2029. [PubMed: 23085812] 
73. Gustavsson P, Hogstedt C, Holmberg B. Mortality and incidence of cancer among Swedish rubber 
workers, 1952–1981. Scand J Work Environ Health 1986;12:538–544. [PubMed: 3823802] 
74. Taeger D, Weiland SK, Sun Y, Keil U, Straif K. Cancer and non-cancer mortality in a cohort of 
recent entrants (1981–2000) to the German rubber industry. Occup Environ Med 2007;64:560–
561. [PubMed: 17634250] 
Thapa et al. Page 14
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
75. Fox AJ, Lindars DC, Owen R. A survey of occupational cancer in the rubber and cablemaking 
industries: results of five-year analysis, 1967–71. Br J Ind Med 1974;31:140–151. [PubMed: 
4830765] 
76. Fox AJ, Collier PF. A survey of occupational cancer in the rubber and cablemaking industries: 
analysis of deaths occurring in 1972–74. Br J Ind Med 1976;33:249–264. [PubMed: 999799] 
77. Schwartz J, Dockery DW, Neas LM. Is daily mortality associated specifically with fine particles? J 
Air Waste Manag Assoc 1996;46: 927–939.
78. Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: 
American College Of Chest Physicians Consensus Statement. Chest 2008;134:1s–41s. [PubMed: 
18779187] 
79. Williams TM, Harris RL, Arp EW, Symons MJ, Van Ert MD. Worker exposure to chemical agents 
in the manufacture of rubber tires and tubes: particulates. Am Ind Hyg Assoc J 1980;41:204–211. 
[PubMed: 7395731] 
80. Karr RM, Davies RJ, Butcher BT, et al. Occupational asthma. J Allergy Clin Immunol 1978;61:54–
65. [PubMed: 618946] 
81. Quirce S Eosinophilic bronchitis in the workplace. Curr Opin Allergy Clin Immunol 2004;4:87–91. 
[PubMed: 15021059] 
82. Wyler C, Braun-Fahrländer C, Künzli N, et al. Exposure to motor vehicle traffic and allergic 
sensitization. Epidemiology 2000;11:450–456. [PubMed: 10874554] 
83. Diaz-Sanchez D, Penichet-Garcia M, Saxon A. Diesel exhaust particles directly induce activated 
mast cells to degranulate and increase histamine levels and symptom severity. J Allergy Clin 
Immunol 2000; 106:1140–1146. [PubMed: 11112898] 
84. Gianniou N, Katsaounou P, Dima E, et al. Prolonged occupational exposure leads to allergic airway 
sensitization and chronic airway and systemic inflammation in professional firefighters. Respir 
Med 2016; 118:7–14. [PubMed: 27578465] 
85. Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med 
2018;197:22–37. [PubMed: 28910134] 
86. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: 
interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit 
Care Med 2011;184:602–615. [PubMed: 21885636] 
87. Shah D Healthy worker effect phenomenon. Indian J Occup Environ Med 2009;13:77–79. 
[PubMed: 20386623] 
88. MacNeil J, Loves RH, Aaron SD. Addressing the misdiagnosis of asthma in adults: where does it 
go wrong? Expert Rev Respir Med 2016;10:1187–1198. [PubMed: 27677224] 
89. Chan-Yeung M, Malo J-L. Occupational asthma. New Eng J Med 1995;333:107–112. [PubMed: 
7777015] 
90. Vermeulen R, Heederik D, Kromhout H, Smit HA. Respiratory symptoms and occupation: a cross-
sectional study of the general population. Environ Health 2002;1:5–5. [PubMed: 12537592] 
91. Galant SP, Komarow HD, Shin H-W, Siddiqui S, Lipworth BJ. The case for impulse oscillometry 
in the management of asthma in children and adults. Ann Allergy Asthma Immunol 
2017;118:664–671. [PubMed: 28583260] 
92. Shirai T, Kurosawa H. Clinical application of the forced oscillation technique. Intern Med 
2016;55:559–566. [PubMed: 26984069] 
93. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 
2006;61:472–477. [PubMed: 16517577] 
94. Buist AS, Vollmer WM. The use of lung function tests in identifying factors that affect lung growth 
and aging. Stat Med 1988;7:11–18. [PubMed: 3353600] 
95. Selikoff IJ, Seidman H. Use of death certificates in epidemiological studies, including occupational 
hazards: variations in discordance of different asbestos-associated diseases on best evidence 
ascertainment. Am J Ind Med 1992;22:481–492. [PubMed: 1442783] 
96. Selikoff IJ. Use of death certificates in epidemiological studies, including occupational hazards: 
discordance with clinical and autopsy findings. Am J Ind Med 1992;22:469–480. [PubMed: 
1442782] 
Thapa et al. Page 15
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
97. De Matteis S, Heederik D, Burdorf A, et al. Current and new challenges in occupational lung 
diseases. Eur Respir Rev 2017;26:170080. [PubMed: 29141963] 
98. Richardson DB. Occupational exposures and lung cancer: adjustment for unmeasured confounding 
by smoking. Epidemiology 2010;21: 181–186. [PubMed: 20081541] 
Thapa et al. Page 16
Am J Ind Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 1. 
Flow diagram illustrating process for inclusion of studies analyzing the association between 
occupational exposure to rubber manufacturing emissions and non-malignant respiratory 
disease. NMRD, non-malignant respiratory disease; SMR, standardized mortality ratio
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FIGURE 2. 
Forest plot of cross-sectional studiesc for the association between occupational exposure to 
rubber manufacturing emissions and development of respiratory symptoms or non-malignant 
respiratory disease. aCaluculated odds ratios and CI from values reported in manuscripts. 
bStudy included multiple odds ratio values so selected highest odds ratio value for a lower 
respiratory symptom. cCross-sectional studies included in the meta-analysis were studies 
that reported odds ratios with CI for respiratory symptoms or NMRDs, or reported data to 
calculate odds ratios and CI. CI, Confidence Interval; NMRD, non-malignant respiratory 
disease
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FIGURE 3. 
Forest plot of mortality studiesa for the association between occupational exposure to rubber 
manufacturing emissions and NMRD-related mortality. aMortality studies that reported 
summary standardized mortality ratios for male employees who died of NMRDs (ICD code: 
427–527). CI, Confidence Interval; NMRD, non-malignant respiratory disease
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po
se
d);
 dy
sp
ne
a =
 86
.7%
 (e
x
po
se
d);
 so
re 
thr
oa
t =
 66
.0%
 (e
x
po
se
d);
 (i
i) 
FE
V1
/FV
C 
(%
) 
=
 7
1.
90
 ±
 1
3.
10
 (a
ctu
al)
 an
d 8
3.0
0 ±
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.00
 (p
red
ict
ed
)
+
Fi
ne
 a
nd
 P
et
er
s 
[1
97
6a
]26
; F
in
e 
an
d 
Pe
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rs
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97
6b
]27
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0
Co
ug
h,
 p
hl
eg
m
, 
w
he
ez
in
g,
 d
ys
pn
ea
, 
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th
m
a
Ye
s
(i)
 C
ou
gh
 = 
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.2%
 (e
x
po
se
d) 
an
d 7
.4%
 (c
on
tro
ls)
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=
 0
.0
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); 
ph
elg
m 
= 2
5.0
% 
(ex
po
se
d) 
an
d 1
2.7
% 
(co
ntr
ols
), (
P 
=
 0
.0
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); 
wh
ee
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g =
 8.
3%
 (e
x
po
se
d) 
an
d 5
.3%
 (c
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tro
ls)
; d
ys
pn
ea
 = 
1.7
% 
(ex
po
se
d) 
an
d 0
% 
(co
ntr
ols
); 
ast
hm
a =
 5.
8%
 (e
x
po
se
d) 
an
d 2
.1%
 (c
on
tro
ls)
; (
ii)
 FE
V1
/ F
VC
 (%
) =
 78
.80
 ± 
6.8
0 (
ex
po
se
d) 
an
d 
79
.2
0 
± 
6.
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 (c
on
tro
ls)
; r
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du
al 
FE
V1
 (m
l) 
= −
16
9 ±
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1 (
ex
po
se
d) 
an
d +
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 ± 
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3 (
co
ntr
ols
), (
P 
=
 0
.0
5);
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ua
l F
V
C 
(m
l) 
= −
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6 ±
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po
se
d) 
an
d +
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 ± 
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6 (
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ntr
ols
), (
P 
=
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.0
1)
+
+
+
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nd
 P
et
er
s 
[1
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4
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ug
h,
 d
ys
pn
ea
, 
w
he
ez
in
g,
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t h
ist
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o
f a
sth
m
a
Ye
s
(i)
 C
ou
gh
 = 
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.0%
 (e
x
po
se
d) 
an
d 7
.4%
 (c
on
tro
ls)
, (P
 
=
 0
.0
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); 
Ph
leg
m
 =
 3
8.
5%
 (e
x
po
se
d) 
an
d 1
2.7
% 
(co
ntr
ols
), (
P 
=
 0
.0
01
); 
wh
ee
zin
g =
 6.
2%
 (e
x
po
se
d) 
an
d 5
.3%
 (c
on
tro
ls)
; p
ast
 hi
sto
ry 
of 
ast
hm
a =
 1.
6 %
 
(ex
po
se
d) 
an
d 2
.1%
 (c
on
tro
ls)
; (
ii)
 FE
V1
/FV
C 
(%
) =
 76
.50
 ± 
8.0
0 (
ex
po
se
d) 
an
d 7
9.2
0 ±
 6.
90
 (c
on
tro
ls)
, (P
 
=
 
0.
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); 
wo
rk
er
s 
>
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 y
ea
rs
 ex
po
su
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, F
EV
1/
FV
C 
(%
) =
 71
.90
% 
(ex
po
se
d) 
an
d 7
8.2
0%
 (c
on
tro
ls)
, (P
 
=
 0
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)
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ne
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l. 
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m
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ez
in
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 d
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ea
, 
pa
st 
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a
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gh
 = 
20
.0%
 (e
x
po
se
d) 
an
d 7
.4%
 (c
on
tro
ls)
, (P
 
=
 0
.0
04
); 
wh
ee
zin
g =
 16
.3%
 (e
x
po
se
d) 
an
d 5
.3%
 
(co
ntr
ols
), (
P 
=
 0
.0
05
); 
ph
leg
m
 =
 3
1.
3%
 (e
x
po
se
d) 
an
d 1
2.7
 %
 (C
on
tro
ls)
, (P
 
=
 0
.0
01
); 
pa
st 
his
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y o
f a
sth
ma
 = 
2.
7%
 (e
x
po
se
d) 
an
d 2
.1%
 (c
on
tro
ls)
 (i
i) 
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ea
rs 
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, re
sid
ua
l F
EV
1 (
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) =
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11
 (e
x
po
se
d) 
an
d +
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(co
ntr
ols
), (
P 
=
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.0
2)
+
+
+
G
am
bl
e 
et
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l. 
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6a
]42
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Co
ug
h,
 p
hl
eg
m
, c
he
st 
pa
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, c
hr
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br
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ch
iti
s
Ye
s
(i)
 C
ou
gh
 = 
30
.0%
 (e
x
po
se
d);
 br
ea
thi
ng
 be
tte
r a
w
ay
 fr
om
 th
e 
w
o
rk
 =
 7
0.
0%
 (e
x
po
se
d),
 (P
 
<
 0
.0
5);
 ch
est
 
tig
ht
ne
ss
 =
 2
7.
0%
 (e
x
po
se
d);
 (i
i) 
cro
ss-
sh
ift
 m
ea
n p
erc
en
t c
ha
ng
e i
n F
EF
50
 (l
ite
rs/
s) 
= −
6.2
0%
 (e
x
po
se
d) 
an
d 
−
2.
80
%
 (c
on
tro
ls)
, (P
 
<
 0
.0
25
); 
FE
F7
5 (
lite
rs/
sec
) =
 −1
7.1
0%
 (e
x
po
se
d) 
an
d −
5.7
0%
 (c
on
tro
ls)
, (P
 
<
 0
.0
05
)
+
G
am
bl
e 
et
 a
l. 
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97
6b
]53
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6
Co
ug
h,
 p
hl
eg
m
, 
br
ea
th
le
ss
ne
ss
Ye
s
(i)
 C
ou
gh
 = 
10
.3%
 (e
x
po
se
d);
 ph
leg
m
 =
 1
5.
1%
 (e
x
po
se
d);
 pe
rsi
ste
nt 
co
ug
h a
nd
 ph
leg
m
 =
 5
.9
%
 (e
x
po
se
d);
 
br
ea
th
le
ss
ne
ss
 =
 2
0.
6%
 (e
x
po
se
d);
 (i
i) 
pre
v
al
en
ce
 o
f i
m
pa
ire
d 
lu
ng
 fu
nc
tio
n 
(F
EV
/FV
C 
< 0
.75
) =
 41
.30
% 
(ex
po
se
d)
+
+
+
G
ov
er
n
a 
et
 a
l. 
[1
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7]
5
79
Cr
os
s-
sh
ift
 c
ha
ng
e 
in
 
pu
lm
on
ar
y 
fu
nc
tio
n
Ye
s
(i)
 ≤5
 ye
ars
 ex
po
su
re
: F
V
C 
(%
 pr
ed
ict
ed
) =
 10
6 ±
 14
 (e
nd
 of
 w
o
rk
 sh
ift
) a
nd
 11
1 ±
 14
 (b
eg
in
ni
ng
 o
f w
o
rk
 
sh
ift
); 
FE
V1
 (%
 pr
ed
ict
ed
) =
 10
7 ±
 18
 (e
nd
 of
 w
o
rk
 sh
ift
) a
nd
 11
1 ±
 18
 (b
eg
in
ni
ng
 o
f
+
G
up
ta
 e
t a
l. 
[1
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3a
]10
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6
Co
ug
hi
ng
 w
ith
 sp
ut
um
, 
ch
es
t p
ai
n,
 
br
ea
th
le
ss
ne
ss
Ye
s
(i)
 C
ou
gh
ing
 w
ith
 sp
utu
m 
= 6
.0%
 (p
ac
ka
gin
g a
nd
 lo
ad
ing
 w
o
rk
er
s),
 7.
0%
 (v
ulc
an
iza
tio
n w
o
rk
er
s),
 an
d 3
.0%
 
(co
mp
ou
nd
ing
 w
o
rk
er
s);
 ch
est
 pa
in 
= 1
7.0
% 
(pa
ck
ag
ing
 an
d l
oa
din
g),
 22
.0 
% 
(vu
lca
niz
ati
on
 w
o
rk
er
s),
 an
d 
25
.0
%
 (c
om
po
un
din
g w
o
rk
er
s);
 br
ea
thl
ess
ne
ss:
 6.
0%
 (p
ac
ka
gin
g a
nd
 lo
ad
ing
), 3
.0%
 (v
ulc
an
iza
tio
n w
o
rk
er
s),
 
an
d 
5.
0%
 (c
om
po
un
din
g);
 vo
m
iti
ng
 w
ith
 b
lo
od
: 4
.0
%
 (p
ac
ka
gin
g a
nd
 lo
ad
ing
), 2
.0%
 (v
ulc
an
iza
tio
n w
o
rk
er
s),
 
an
d 
4.
0%
 (c
om
po
un
din
g w
o
rk
er
s);
 (i
i) 
Ra
w
 (a
irw
ay
 re
sis
ta
nc
e) 
me
an
 ± 
SD
 = 
1.5
1 ±
 0.
45
 (p
ac
ka
gin
g a
nd
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R
ef
er
en
ce
s
N
o.
 o
f 
w
o
rk
er
s
Sy
m
pt
om
s/d
ia
gn
os
is
PF
T
Fi
nd
in
gs
a
St
re
n
gt
h 
of
 
ev
id
en
ce
b
lo
ad
in
g 
w
o
rk
er
s),
 1.
82
 ± 
0.8
6 (
vu
lca
niz
ati
on
 w
o
rk
er
s),
 an
d 2
.12
 ± 
0.8
6 (
co
mp
ou
nd
ing
 w
o
rk
er
s);
 ch
an
ge
s i
n 
lu
ng
 fu
nc
tio
n 
ty
pi
ca
l o
f o
bs
tru
ct
io
n 
le
ad
s t
o 
an
 in
cr
ea
se
 in
 ra
w
 v
al
ue
G
up
ta
 e
t a
l. 
[1
99
3b
]43
66
7
B
re
at
hi
ng
 p
ro
bl
em
s, 
ch
es
t p
ai
ns
, c
he
st 
irr
ita
tio
n,
 c
ou
gh
, 
sp
ut
um
, b
lo
od
 
v
o
m
iti
ng
Ye
s
(i)
 B
rea
thi
ng
 pr
ob
lem
s, 
ch
est
 pa
in 
(pa
ck
ag
ing
 an
d l
oa
din
g w
o
rk
er
s),
 vo
m
iti
ng
 b
lo
od
, b
re
at
hi
ng
 p
ro
bl
em
s, 
ch
es
t 
pa
in
, c
ou
gh
 a
nd
 sp
ut
um
 w
ith
 b
lo
od
 (v
ulc
an
izi
ng
 w
o
rk
er
s),
 an
d b
rea
thi
ng
 pr
ob
lem
s, 
ch
est
 pa
in,
 ch
est
 ir
rit
ati
on
, 
co
u
gh
 a
nd
 sp
ut
um
 w
ith
 b
lo
od
, t
hr
oa
t i
rri
ta
tio
n 
(co
mp
ou
nd
ing
 w
o
rk
er
s):
 sp
ec
ifi
c 
nu
m
be
rs
 w
er
e 
no
t p
ro
v
id
ed
; 
(ii
) F
EV
1/ 
FV
C 
(%
) (
Le
ng
th 
of 
em
plo
ym
en
t >
6 
ye
ar
s) 
= 9
1.5
0 ±
 7.
50
 (p
ac
ka
gin
g a
nd
 lo
ad
ing
 w
o
rk
er
s),
 89
.90
 
±
 1
2.
30
 (v
ulc
an
iza
tio
n w
o
rk
er
s),
 an
d 8
9.1
0 ±
 17
.10
 (c
om
po
un
din
g w
o
rk
er
s)
+
G
up
ta
 e
t a
l. 
[1
99
4]
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66
7
Lu
ng
 o
bs
tru
ct
io
n 
an
d 
re
st
ric
tio
n
Ye
s
(i)
 RV
(l)
 = 
1.0
8, 
TL
C(
l) 
= 3
.73
, R
V
/T
LC
 ra
tio
 =
 2
8.
95
, a
nd
 F
RC
(l)
 = 
2.0
0 (
pa
ck
ag
ing
 an
d l
oa
din
g w
o
rk
er
s),
 
RV
(l)
 = 
1.0
9, 
TL
C(
l) 
= 3
.64
, R
V
/T
LC
 =
 2
9.
95
,an
d 
FR
C(
l) 
= 2
.01
 (v
ulc
an
izi
ng
 w
o
rk
er
s),
 an
d R
V
(l)
 = 
1.2
2, 
TL
C(
l) 
= 3
.31
, R
V
/T
LC
 =
 3
6.
86
, F
RC
(l)
 = 
2.1
2 (
co
mp
ou
nd
ing
 w
o
rk
er
s)
+
H
ni
zd
o 
et
 a
l. 
[2
00
2]
3
71
CO
PD
N
o
(i)
 C
OP
D,
 O
R 
(95
%C
I) 
= 2
.5 
(1.
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4.4
)
+
+
Jo
ns
so
n 
et
 a
l. 
[2
00
7]
6
28
3
Th
ro
at
 b
u
rn
in
g,
 c
ou
gh
, 
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ne
a,
 w
he
ez
in
g,
 
ch
es
t t
ig
ht
ne
ss
N
o
(i)
 C
ou
gh
, O
R 
(95
%C
I) 
= 3
.8 
(1.
9–
7.7
) (
ex
po
se
d),
 3.
6 (
1.5
–8
.7)
 (l
ow
 T
TC
A
 le
v
el
 ex
po
se
d),
 5.
1 (
2.2
–1
2.0
) 
(in
ter
me
dia
te 
TT
CA
 le
v
el
 ex
po
se
d),
 an
d 3
.0 
(1.
3–
7.2
) (
hig
h T
TC
A 
lev
el
 ex
po
se
d),
 (P
 
≤ 
0.
05
); 
dy
sp
ne
a, 
w
he
ez
in
g,
 o
r c
he
st 
tig
ht
ne
ss
, O
R 
(95
%C
I) 
= 1
.2 
(0.
6–
2.2
) (
ex
po
se
d),
 1.
2 (
0.5
–2
.6)
 (l
ow
 T
TC
A
 le
v
el
 ex
po
se
d),
 
0.
9 
(0.
3–
2.2
) (
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iat
e T
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A 
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d),
 an
d 1
.3 
(0.
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2.8
) (
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et
 a
l. 
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8a
]12
26
2
N
os
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en
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s
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o
N
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, O
R 
(95
%C
I) 
= 2
.9 
(1.
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8.3
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ex
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se
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o
rk
er
s)
+
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so
n 
et
 a
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ro
at
 b
u
rn
in
g,
 c
ou
gh
, 
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a,
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he
ez
in
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ch
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t t
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ht
ne
ss
N
o
(i)
 C
ou
gh
, O
R 
(95
%C
I) 
= 3
.3 
(1.
3–
8.3
) (
low
 1
-H
P 
le
v
el
 ex
po
se
d),
 3.
6 (
1.5
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.0)
 (i
nte
rm
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e 1
-H
P l
ev
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ex
po
se
d),
 an
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.9 
(2.
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.0)
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 1-
HP
 le
v
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 ex
po
se
d);
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ne
a, 
wh
ee
ze
, o
r c
he
st 
tig
htn
ess
, O
R 
(95
%C
I) 
= 
1.
5 
(0.
6–
3.3
) (
low
 1
-H
P 
le
v
el
 ex
po
se
d),
 1.
1 (
0.4
–2
.4)
 (i
nte
rm
ed
iat
e 1
-H
P l
ev
el
 ex
po
se
d),
 an
d 1
.3 
(0.
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2.8
) 
(hi
gh
 1-
HP
 le
v
el
 ex
po
se
d)
+
+
Jo
ns
so
n 
et
 a
l. 
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00
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]47
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Lu
ng
 im
pa
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en
t
Ye
s
(i)
 FV
C 
(%
), (
me
an
, ra
ng
e) 
= 9
5, 
57
–1
29
 (e
x
po
se
d) 
an
d 9
7, 
50
–1
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 (c
on
tro
ls)
+
Jo
ns
so
n 
et
 a
l. 
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00
9]
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29
0
Th
ro
at
 b
u
rn
in
g 
an
d 
dr
yn
es
s, 
ho
ar
se
ne
ss
, 
se
v
er
e 
dr
y 
co
ug
h,
 
dy
sp
ne
a,
 w
he
ez
in
g,
 
ch
es
t t
ig
ht
ne
ss
N
o
(i)
 T
hro
at 
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rn
in
g 
an
d 
dr
yn
es
s, 
O
R 
(95
%C
I) 
= 3
.2 
(1.
7–
6.1
) (
ex
po
se
d),
 3.
7 (
1.7
–7
.7)
 (l
ow
 N
-n
itr
os
am
in
es
 le
v
el
 
ex
po
se
d),
 3.
4 (
1.5
–7
.4)
 (i
nte
rm
ed
iat
e N
-ni
tro
sam
ine
s l
ev
el
 ex
po
se
d),
 an
d 2
.6 
(1.
1–
5.9
) (
hig
h N
-ni
tro
sam
ine
s 
le
v
el
 ex
po
se
d),
 (P
 
≤ 
0.
05
); 
co
ug
h, 
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 (9
5%
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) =
 3.
9 (
1.9
–7
.8)
 (e
x
po
se
d),
 4.
0 (
1.8
–9
.2)
 (l
ow
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-n
itr
os
am
in
es
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v
el
 ex
po
se
d),
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1 (
2.2
–1
2) 
(in
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te 
N-
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ine
s l
ev
el
 ex
po
se
d),
 an
d 2
.7 
(1.
1–
6.7
) (
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h N
-
n
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v
el
 ex
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se
d),
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≤ 
0.
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); 
dy
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ne
a, 
wh
ee
zin
g a
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/or
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 tig
htn
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, O
R 
(95
%C
I) 
= 1
.2 
(0.
6–
2.2
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(ex
po
se
d),
 1.
1 (
0.4
–2
.3)
 (l
ow
 N
-n
itr
os
am
in
es
 le
v
el
 ex
po
se
d),
 1.
5 (
0.7
–3
.3)
 (i
nte
rm
ed
iat
e N
-ni
tro
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ine
s l
ev
el
 
ex
po
se
d),
 an
d 1
.2 
(0.
5–
2.8
) (
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h N
-ni
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ine
s l
ev
el
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po
se
d)
+
+
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ar
 e
t a
l. 
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Em
ph
ys
em
a,
 a
sth
m
a
N
o
(i)
 To
ta
l r
et
ire
es
 d
ue
 to
 p
ul
m
on
ar
y 
di
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bi
lit
y, 
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ph
ys
em
a 
= 
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.4
%
, a
sth
m
a =
 1
1.
0%
, a
nd
 o
th
er
 p
ul
m
on
ar
y 
co
n
di
tio
ns
 =
 2
1.
9%
+
M
cM
ic
ha
el
 e
t a
l. 
[1
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6]
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18
20
Co
ug
h,
 p
hl
eg
m
, c
he
st 
ill
ne
ss
Ye
s
(i)
 C
ou
gh
 = 
16
.3%
 (r
ub
be
r w
o
rk
er
s) 
an
d 1
0.9
% 
(po
sta
l w
o
rk
er
s);
 ph
leg
m
 =
 2
1.
9%
 (r
ub
be
r w
o
rk
er
s) 
an
d 1
0.0
% 
(po
sta
l w
o
rk
er
s);
 pe
rsi
ste
nt 
co
ug
h, 
ph
leg
m
 a
nd
 c
he
st 
ill
ne
ss
 =
 8
.1
%
 (r
ub
be
r w
o
rk
er
s) 
an
d 4
.1%
 (p
os
tal
 
w
o
rk
er
s);
 (i
i) 
W
o
rk
er
s 
re
po
rti
ng
 re
sp
ira
to
ry
 sy
m
pt
om
s h
ad
 lo
w
er
 F
EV
1 
th
an
 a
sy
m
pt
om
at
ic
 w
o
rk
er
s
+
M
ei
jer
 et
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9
Co
ug
h,
 p
hl
eg
m
, 
dy
sp
ne
a,
 w
he
ez
e,
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th
m
at
ic
 a
tta
ck
Ye
s
(i)
 C
ou
gh
 an
d/o
r p
hle
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 =
 3
.0
%
 (e
x
po
se
d 
no
n/
ex
-s
m
o
ke
r),
 13
.0%
 (e
x
po
se
d 
sm
ok
er
), 8
.0%
 (n
on
/ex
-s
m
o
ke
r 
co
n
tr
ol
s),
 an
d 1
6.0
% 
(sm
ok
er
 c
o
n
tr
ol
s);
 dy
sp
ne
a a
nd
/or
 w
he
ez
e =
 19
.0%
 (e
x
po
se
d 
no
n/
ex
-s
m
o
ke
r),
 21
.0%
 
(ex
po
se
d 
sm
ok
er
), 1
3.0
% 
(no
n/e
x
-s
m
o
ke
r 
co
n
tr
ol
s),
 an
d 1
9.0
% 
(sm
ok
er
 c
o
n
tr
ol
s);
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c a
tta
ck
 = 
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.0%
 
(ex
po
se
d 
no
n/
ex
-s
m
o
ke
r),
 5.
0%
 (e
x
po
se
d 
sm
ok
er
), 8
.0%
 (n
on
/ex
-s
m
o
ke
r 
co
n
tr
ol
s),
 an
d 1
3.0
% 
(sm
ok
er
 
co
n
tr
ol
s);
 (i
i) 
FE
V1
/ F
VC
 (%
) =
 79
.90
 (e
x
po
se
d) 
an
d 8
1.9
0 (
co
ntr
ols
), (
P 
<
 0
.0
5)
+
+
N
eg
ha
b 
et
 a
l. 
[2
01
1]
48
14
1
Co
ug
h,
 p
hl
eg
m
, 
w
he
ez
in
g,
 d
ys
pn
ea
Ye
s
(i)
 C
ou
gh
 = 
23
.6%
 (e
x
po
se
d) 
an
d 1
.4%
 (c
on
tro
ls)
; p
hle
gm
 =
 4
1.
6%
 (e
x
po
se
d) 
an
d 5
.7%
 (c
on
tro
ls)
; p
rod
uc
tiv
e 
co
u
gh
 =
 2
5.
0%
 (e
x
po
se
d) 
an
d 2
.8%
 (c
on
tro
ls)
; w
he
ez
ing
 = 
25
.0 
% 
(ex
po
se
d) 
an
d 1
.4%
 (c
on
tro
ls)
; d
ys
pn
ea
 = 
31
.9
 %
 (e
x
po
se
d) 
an
d 0
% 
(co
ntr
ols
), (
P 
=
 0
.0
00
1);
 (i
i) 
FE
V1
/ F
VC
 (%
) =
 98
.30
 ± 
12
.33
 (e
x
po
se
d) 
an
d 1
01
.92
 
±
 9
.7
1 
(co
ntr
ols
), (
P 
<
 0
.0
5)
+
+
+
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R
ef
er
en
ce
s
N
o.
 o
f 
w
o
rk
er
s
Sy
m
pt
om
s/d
ia
gn
os
is
PF
T
Fi
nd
in
gs
a
St
re
n
gt
h 
of
 
ev
id
en
ce
b
N
eg
ha
b 
et
 a
l. 
[2
00
7]
49
20
7
Co
ug
h,
 p
hl
eg
m
, 
br
ea
th
le
ss
ne
ss
, 
w
he
ez
in
g
Ye
s
(i)
 C
ou
gh
 = 
15
.6%
 (e
x
po
se
d 
no
n-
sm
ok
er
s),
 42
.4%
 (e
x
po
se
d 
sm
ok
er
s),
 5.
4%
 (n
on
-sm
ok
er
s 
co
n
tr
ol
s),
 an
d 
13
.5
%
 (s
mo
ke
r 
co
n
tr
ol
s);
 ph
leg
m
 =
 1
7.
1%
 (e
x
po
se
d 
no
n-
sm
ok
er
s),
 48
.4%
 (e
x
po
se
d 
sm
ok
er
s),
 8.
2%
 (n
on
-
sm
o
ke
rs
 c
o
n
tr
ol
s),
 an
d 1
8.9
% 
(sm
ok
er
 c
o
n
tr
ol
s);
 pr
od
uc
tiv
e 
co
u
gh
 =
 6
.2
%
 (e
x
po
se
d 
no
n-
sm
ok
er
s),
 27
.3%
 
(ex
po
se
d 
sm
ok
er
s),
 2.
7%
 (n
on
-sm
ok
er
s 
co
n
tr
ol
s),
 an
d 5
.4%
 (s
mo
ke
r 
co
n
tr
ol
s);
 br
ea
thl
ess
ne
ss 
= 1
0.9
% 
(ex
po
se
d 
no
n-
sm
ok
er
s),
 36
.3%
 (e
x
po
se
d 
sm
ok
er
s),
 8.
2%
 (n
on
-sm
ok
er
s 
co
n
tr
ol
s),
 an
d 1
0.8
% 
(sm
ok
er
 
co
n
tr
ol
s),
 (P
 
<
 0
.0
01
); 
(ii
) V
C 
(%
) =
 79
.78
 (e
x
po
se
d) 
an
d 9
0.6
5 (
un
ex
po
se
d),
 (P
 
<
0.
00
01
); 
FV
C 
(%
) =
 80
.30
 
(ex
po
se
d) 
an
d 9
1.9
0 (
un
ex
po
se
d) 
(P
 
<
0.
00
01
); 
FE
V1
 (%
) =
 79
.87
 (e
x
po
se
d) 
an
d 9
1.4
1 (
un
ex
po
se
d),
 (P
 
<
0.
00
01
)
+
+
+
Sp
ar
ks
 e
t a
l. 
[1
98
2]
50
37
0
W
he
ez
in
g,
 d
ys
pn
ea
, 
co
u
gh
, c
he
st 
tig
ht
ne
ss
, 
ch
ro
ni
c 
br
on
ch
iti
es
Ye
s
(i)
 C
hro
nic
 br
on
ch
itis
 = 
13
.3%
 (h
igh
 du
st 
ex
po
se
d),
 32
.5%
 (m
ed
ium
 du
st 
an
d f
um
es 
ex
po
se
d),
 an
d 1
9.0
% 
(lo
w
 
du
st 
ex
po
se
d),
 (P
 
<
 0
.0
5);
 lo
os
e o
r p
rod
uc
tiv
e 
co
u
gh
 =
 3
5.
5%
 (h
igh
 du
st 
ex
po
se
d),
 42
.5%
 (m
ed
ium
 du
st 
an
d 
fu
m
es
 ex
po
se
d),
 an
d 2
9.3
% 
(lo
w
 d
us
t e
x
po
se
d) 
(P
 
<
 0
.0
5);
 w
he
ez
ing
 = 
4.5
% 
(hi
gh
 du
st 
ex
po
se
d),
 2.
7%
 
(m
ed
ium
 du
st 
an
d f
um
es 
ex
po
se
d),
 an
d 4
.8%
 (l
ow
 d
us
t e
x
po
se
d);
 ch
est
 tig
htn
ess
 = 
23
.9%
 (h
igh
 du
st 
ex
po
se
d);
 
22
.7
%
 (m
ed
ium
 du
st 
an
d f
um
es 
ex
po
se
d),
 an
d 1
6.7
% 
(lo
w
 d
us
t e
x
po
se
d) 
(ii
) m
ea
n r
ati
o o
f F
EV
1/±
SE
: 0
.79
5 
±
 0
.0
01
 (h
igh
 du
st 
ex
po
se
d),
 0.
78
6 ±
 0.
00
1 (
me
diu
m 
du
st 
an
d f
um
es 
ex
po
se
d),
 an
d 0
.79
0 ±
 0.
00
1 (
low
 d
us
t 
ex
po
se
d)
+
+
Sz
ub
er
t e
t a
l. 
[1
99
8]
52
97
3
N
R
N
o
(i)
 Si
ck
ne
ss 
ab
sen
ce
 am
on
g a
ll w
o
rk
er
s 
(re
sp
ira
tor
y d
ise
ase
) =
 17
.2%
; d
iff
er
en
ce
 in
 lo
st 
tim
e 
ra
te
 b
et
w
ee
n 
m
an
u
fa
ct
ur
in
g 
an
d 
ot
he
r d
ep
ar
tm
en
t w
o
rk
er
s 
w
ith
 re
sp
ec
t t
o 
re
sp
ira
to
ry
 d
ise
as
es
 =
 7
5.
0%
+
Th
om
as
 e
t a
l. 
[1
98
6]
51
21
7
N
as
al
 c
on
ge
sti
on
, 
ph
ar
yn
gi
tis
, c
ou
gh
, 
w
he
ez
in
g,
 d
ys
pn
ea
N
o
(i)
 ≤2
5 a
ge
, s
ym
pto
ma
tic
 = 
14
 (t
he
rm
oin
jec
tio
n w
o
rk
er
s) 
an
d 3
 (o
the
r);
 as
ym
pto
ma
tic
 = 
15
 (t
he
rm
oin
jec
tio
n 
w
o
rk
er
s) 
an
d 5
2 (
oth
er)
, O
R 
(95
%C
I) 
= 1
6 (
4.1
–6
3.0
); 
>2
5 a
ge
, s
ym
pto
ma
tic
 = 
7 (
the
rm
oin
jec
tio
n w
o
rk
er
s) 
an
d 
1 
(ot
he
r);
 as
ym
pto
ma
tic
 = 
19
 (t
he
rm
oin
jec
tio
n w
o
rk
er
s) 
an
d 1
06
 (o
the
r),
 O
R 
(95
%C
I) 
= 3
9 (
3.7
–4
14
.0)
+
+
W
ee
ks
 e
t a
l. 
[1
98
1a
]28
;
W
ee
ks
 e
t a
l. 
[1
98
1b
]29
74
4
Sh
or
tn
es
s o
f b
re
at
h,
 
co
u
gh
, s
pu
tu
m
, 
w
he
ez
e,
 c
he
st 
tig
ht
ne
ss
Ye
s
(i)
 Sh
ort
ne
ss 
of 
bre
ath
, C
I =
 0.
4–
1.8
 (c
uri
ng
 w
o
rk
er
s);
 w
he
ez
e, 
CI
 = 
1.1
–2
.5 
(cu
rin
g w
o
rk
er
s) 
an
d O
/E
 = 
1.3
 
(m
illi
ng
 w
o
rk
er
s);
 co
ug
h, 
CI
 = 
0.8
–2
.1 
(cu
rin
g w
o
rk
er
s) 
an
d O
/E
 = 
1.4
 (m
illi
ng
 w
o
rk
er
s);
 sp
utu
m,
 C
I =
 0.
9–
3.
1 
(cu
rin
g w
o
rk
er
s);
 ch
est
 tig
htn
ess
, C
I =
 1.
8–
5.2
 an
d O
/E
 = 
1.5
 (m
illi
ng
 w
o
rk
er
s);
 sp
utu
m,
 O
/E
 = 
1.7
 
(m
illi
ng
 w
o
rk
er
s),
 (P
 
<
 0
.0
5);
 (i
i) 
los
s o
f F
EV
1 a
t a
bo
ut 
12
 m
L 
pe
r c
uri
ng
 ye
ar 
(cu
rin
g w
o
rk
er
s),
 (P
 
=
 0
.0
36
) 
an
d 
lo
ss
 o
f F
V
C 
at
 a
bo
ut
 1
2 
m
L 
pe
r c
ur
in
g 
ye
ar
 (c
uri
ng
 w
o
rk
er
s),
 (P
 
=
 0
.0
42
); 
FE
V1
, O
/E
 = 
1.3
0 a
nd
 FV
C,
 
O
/E
 =
 1
.0
0 
(m
illi
ng
 w
o
rk
er
s),
 (P
 
<
 0
.0
5)
+
+
+
Zu
sk
in
 e
t a
l. 
[1
99
6]
15
58
1
Si
nu
sit
ie
s, 
co
ug
h,
 
ph
le
gm
, d
ys
pn
ea
, 
ch
ro
ni
c 
br
on
ch
iti
es
, 
o
cc
u
pa
tio
na
l a
sth
m
a
Ye
s
(i)
 Si
nu
sit
ies
 = 
23
.7%
 (e
x
po
se
d) 
an
d 2
.9%
 (c
on
tro
ls)
, (P
 
<
 0
.0
1);
 co
ug
h =
 52
.6%
 (e
x
po
se
d) 
an
d 2
6.2
% 
(co
ntr
ols
), (
P 
<
 0
.0
1);
 ph
leg
m
 =
 5
1.
8%
 (e
x
po
se
d) 
an
d 3
5 %
 (c
on
tro
ls)
 (P
 
<
 0
.0
1);
 dy
sp
ne
a =
 63
.6%
 (e
x
po
se
d) 
an
d 
29
.1
%
 (c
on
tro
ls)
, (P
 
<
 0
.0
1);
 ch
ron
ic 
bro
nc
hit
is 
= 4
8.9
% 
(ex
po
se
d) 
an
d 2
3.3
% 
(co
ntr
ols
), (
P 
<
 0
.0
1);
 
o
cc
u
pa
tio
na
l a
sth
m
a 
= 
5.
1%
 (e
x
po
se
d) 
an
d 0
% 
(co
ntr
ols
); 
(ii
) F
VC
 (%
) =
 D
iff
er
en
ce
 b
ef
or
e-
af
te
r s
hi
ft:
 −
3.
7 
(ex
po
se
d 
sm
ok
er
), −
1.8
0 (
ex
po
se
d 
no
n-
sm
ok
er
), −
0.4
0 (
sm
ok
er
 c
o
n
tr
ol
s),
 an
d −
0.6
0 (
no
n-s
mo
ke
r 
co
n
tr
ol
s),
 (P
 
<
 0
.0
1)
+
+
+
CI
, c
on
fid
en
ce
 in
te
rv
al
; C
O
PD
, C
hr
on
ic
 O
bs
tru
ct
iv
e 
Pu
lm
on
ar
y 
D
ise
as
e;
 F
EV
1,
 fo
rc
ed
 ex
pi
ra
to
ry
 v
o
lu
m
e 
in
 1
 se
cs
; F
EF
50
, f
or
ce
d 
ex
pi
ra
to
ry
 fl
ow
 a
t 5
0%
 o
f F
V
C;
 F
EF
75
, f
or
ce
d 
ex
pi
ra
to
ry
 fl
ow
 a
t 7
5%
 o
f 
FV
C;
 F
V
C,
 fo
rc
ed
 v
ita
l c
ap
ac
ity
; F
RC
, f
un
ct
io
na
l r
es
id
ua
l c
ap
ac
ity
; m
l, 
m
ill
ili
te
rs
; N
R,
 n
ot
 re
po
rte
d;
 N
S,
 n
on
-s
ig
ni
fic
an
t (
P 
≥ 
0.
05
); 
OR
, o
dd
s r
ati
o; 
O/
E,
 ob
ser
ve
d/
 ex
pe
ct
ed
; P
M
, p
ar
tic
ul
at
e 
m
at
te
r; 
PA
H
s, 
po
ly
ar
om
at
ic
 h
yd
ro
ca
rb
on
s; 
PF
T,
 
pu
lm
on
ar
y 
fu
nc
tio
n 
te
sti
ng
; P
V
C,
 p
ol
yv
in
yl
 c
hl
or
id
e;
 R
V,
 
re
sid
ua
l v
o
lu
m
e;
 S
D
, s
ta
nd
ar
d 
de
v
ia
tio
n;
 S
E,
 st
an
da
rd
 e
rro
r; 
TL
C,
 to
ta
l l
un
g 
ca
pa
ci
ty
; V
C,
 v
ita
l c
ap
ac
ity
; 1
-H
P,
 
1-
hy
dr
ox
yp
yr
en
e;
 T
TC
A
, 2
-th
io
th
ia
zo
lid
in
e-
4-
ca
rb
ox
yl
ic
 a
ci
d.
 R
es
id
ua
l, 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
pr
ed
ic
te
d 
an
d 
th
e 
ac
tu
al
 v
al
ue
 o
f a
 p
ul
m
on
ar
y 
fu
nc
tio
n 
te
st;
 re
sid
ua
l F
EV
1 
an
d 
FV
C,
 b
as
ed
 o
n 
a 
m
ul
tip
le
 
re
gr
es
sio
n 
eq
ua
tio
n 
de
riv
ed
 fr
om
 th
e 
no
n-
bl
ac
k 
co
nt
ro
l r
ub
be
r w
o
rk
er
s 
o
v
er
 2
4 
ye
ar
s o
f a
ge
, a
dju
ste
d f
or 
the
 m
ajo
r c
on
fou
nd
ing
 va
ria
bl
es
: a
ge
, h
ei
gh
t, 
an
d 
ye
ar
s o
f c
ig
ar
et
te
 s
m
ok
in
g 
be
tw
ee
n 
th
e 
tw
o
 
gr
ou
ps
 o
f e
x
po
se
d 
an
d 
co
nt
ro
l w
o
rk
er
s.
 U
pp
er
 re
sp
ira
to
ry
 sy
m
pt
om
s (
no
seb
lee
d, 
na
sal
 co
ng
est
ion
, th
roa
t b
u
rn
in
g 
an
d 
dr
yn
es
s, 
ho
ar
se
ne
ss
, p
ha
ry
ng
iti
s, 
an
d 
sin
us
iti
s) 
an
d l
ow
er
 r
es
pi
ra
to
ry
 sy
m
pt
om
s 
(co
ug
h, 
sp
utu
m 
pro
du
cti
on
, d
ys
pn
ea
, w
he
ez
ing
, c
he
st 
tig
htn
ess
, p
hle
gm
, c
he
st 
irr
ita
tio
n,
 c
he
st 
pa
in
, b
re
at
hl
es
sn
es
s, 
an
d 
sh
or
tn
es
s o
f b
re
at
h).
a F
in
di
ng
s r
ep
or
te
d 
in
 p
ub
lic
at
io
ns
.
b S
tre
ng
th
 o
f e
v
id
en
ce
 fo
r p
os
iti
v
e 
as
so
ci
at
io
n:
 +
++
, s
tro
ng
; +
+,
 in
te
rm
ed
ia
te
; +
, n
on
-s
ig
ni
fic
an
t p
os
iti
v
e 
as
so
ci
at
io
n;
 N
A
, n
o 
as
so
ci
at
io
n;
 d
ef
in
iti
on
s-
Ta
bl
e 
1.
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TA
B
LE
 4
N
on
-m
al
ig
na
nt
 re
sp
ira
to
ry
 d
ise
as
e-
re
la
te
d 
m
or
ta
lit
y 
am
on
g 
ru
bb
er
 m
an
uf
ac
tu
rin
g 
co
ho
rts
C
oh
or
t a
nd
 re
fe
re
n
ce
N
o.
 o
f 
w
o
rk
er
s
R
eq
ui
re
d 
te
nu
re
Fi
nd
in
gs
St
re
n
gt
h 
of
 
ev
id
en
ce
a
A
—
A
nd
jel
ko
v
ic
h 
et
 a
l. 
[1
97
8]
54
16
49
Em
pl
oy
ed
 o
r r
et
ire
d
(i)
 W
hit
e f
em
ale
s, 
40
–8
4 y
ea
rs 
ag
e c
ate
go
ry
,
 
19
64
–1
97
3;
 (i
i) 
pn
eu
mo
nia
b ,
 
SM
R,
 0
.6
6 
(95
%C
I, 0
.24
–
1.
47
); 
(ii
i) 
bro
nc
hit
is,
 em
ph
ys
em
a,
 a
nd
 a
sth
m
a,
 S
M
R,
 1
.0
5 
(95
%C
I, 0
.26
–2
.86
); 
(iv
) N
M
RD
, S
M
R,
 1.
96
 
(95
%C
I, 0
.50
–5
.40
)
+
A
—
A
nd
jel
ko
v
ic
h 
et
 a
l. 
[1
97
6]
55
23
73
Em
pl
oy
ed
 o
r r
et
ire
d
(i)
 W
hit
e m
ale
s, 
ret
ire
d g
rou
p, 
40
–6
4 y
ea
rs 
ag
e c
ate
go
ry
,
 
19
64
–1
97
3;
 (i
i) 
pn
eu
mo
nia
b ,
 
SM
R,
 0
.8
8 
(95
%C
I, 0
.22
–2
.40
) (
iii)
 br
on
ch
itis
, a
sth
ma
, a
nd
 em
ph
ys
em
a,
 S
M
R,
 1
.8
4 
(95
%C
I, 1
.43
–2
.40
); 
(iv
) 
N
M
RD
, S
M
R,
 3
.0
9 
(95
%C
I, 1
.80
–5
.08
)
+
+
A
—
M
cM
ic
ha
el
 e
t a
l. 
[1
97
4]
56
66
78
Em
pl
oy
ed
 o
r r
et
ire
d
(i)
 W
hit
e m
ale
s, 
40
–6
4 y
ea
rs 
ag
e c
ate
go
ry
,
 
19
64
–1
97
2;
 (i
i) 
ch
ron
ic 
res
pir
ato
ry 
dis
ea
ses
, S
M
R,
 0.
96
 
(95
%C
I, 0
.53
–1
.59
)
N
A
B
—
B
ea
ll 
et
 a
l. 
[2
00
7]
57
34
25
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s h
ire
d 
in
 o
r a
fte
r 1
96
2;
 (i
i) 
NM
RD
, S
M
R,
 0.
51
 (9
5%
CI
, 0
.30
–0
.80
) (
tot
al 
em
plo
ye
es
) 
an
d 
0.
52
 (9
5%
CI
, 0
.31
–0
.83
) (
ma
le)
N
A
C—
D
el
ze
ll 
an
d 
M
on
so
n 
[1
98
2a
]58
26
66
≥2
 y
ea
rs
(i)
 W
hit
e m
ale
s, 
pro
ce
ssi
ng
 w
o
rk
er
s,
 1
94
0–
19
71
; (
ii)
 N
M
RD
, S
M
R,
 0.
84
 (9
5%
 C
I, 0
.64
–1
.08
); 
(ii
i) 
em
ph
ys
em
a,
 S
M
R,
 1
.1
8 
(95
%C
I, 0
.75
–1
.77
)
+
C—
 D
el
ze
ll 
an
d 
M
on
so
n 
[1
98
2b
]59
32
7
≥2
 y
ea
rs
(i)
 W
hit
e m
ale
s, 
ex
po
se
d 
to
 a
cr
yl
on
itr
ile
, 1
94
0–
19
71
; (
ii)
 N
M
RD
, S
M
R,
 1.
04
 (9
5%
CI
, 0
.30
–2
.40
)
+
C—
D
el
ze
ll 
an
d 
M
on
so
n 
[1
98
4]
60
31
61
≥2
 y
ea
rs
(i)
) W
hit
e m
ale
s, 
ae
ros
pa
ce
 w
o
rk
er
s,
 1
94
0–
19
71
; (
ii)
 N
M
RD
, S
M
R,
 0.
80
 (9
5%
 C
I, 0
.60
–1
.00
)
N
A
C—
D
el
ze
ll 
an
d 
M
on
so
n 
[1
98
5a
]61
17
90
≥2
 y
ea
rs
(i)
 W
hit
e m
ale
s, 
rec
lai
m 
div
isi
on
 w
o
rk
er
s,
 1
94
0–
19
71
; (
ii)
 N
M
RD
, S
M
R,
 0.
90
 (9
5%
CI
, 0
.60
–1
.30
); 
(ii
i) 
em
ph
ys
em
a,
 S
M
R,
 1
.3
0 
(95
%C
I, 0
.60
–2
.40
)
+
C—
D
el
ze
ll 
an
d 
M
on
so
n 
[1
98
5b
]62
11
52
≥2
 y
ea
rs
(i)
 W
hit
e m
ale
s, 
cu
rin
g w
o
rk
er
s,
 1
94
0–
19
71
;(i
i) 
em
ph
ys
em
a,
 S
M
R,
 0
.8
0 
(95
% 
CI
, 0
.30
–1
.70
); 
(ii
i) 
N
M
RD
, S
M
R,
 1
.1
0 
(95
%C
I, 0
.80
–1
.60
); 
(ii
i) 
pn
eu
mo
nia
 (c
uri
ng
 w
o
rk
er
s 
co
m
pa
re
d 
to
 n
on
-c
ur
in
g 
w
o
rk
er
s),
 SM
R,
 2.
20
 (9
5%
CI
, 1
.37
–3
.38
)
+
+
+
C—
M
on
so
n 
an
d 
N
ak
an
o 
[1
97
6]
63
13
57
1
≥5
 y
ea
rs
(i)
 W
hit
e m
ale
s, 
19
40
–1
97
4; 
(ii
) N
M
RD
, S
M
R,
 0.
68
 (0
.59
–0
.77
); 
(ii
i) 
ast
hm
a, 
SM
R,
 1.
60
 (9
5%
CI
, 
0.
82
–2
.7
3);
 (iv
) p
ne
um
on
ia,
 SM
R,
 1.
60
 (9
5%
CI
, 0
.84
–2
.64
)
+
D
—
D
os
t e
t a
l. 
[2
00
7]
64
86
51
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
83
–2
00
4;
 (i
i) 
NM
RD
, S
M
R,
 1.
24
 (9
5%
CI
, 0
.82
–1
.79
) (
ma
le)
 an
d 1
.70
 (9
5%
CI
, 
0.
55
–3
.9
7) 
(fe
ma
le)
+
D
—
St
ra
ug
ha
n 
an
d 
So
ra
ha
n 
[2
00
0]
65
86
51
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
83
–1
99
8;
 (i
i) 
NM
RD
, S
M
R,
 1.
12
 (9
5%
CI
, 0
.60
–1
.80
) (
ma
le)
 an
d 0
.81
 (9
5%
CI
, 
0.
04
–4
.0
1) 
(fe
ma
le)
+
E—
Pi
ra
 e
t a
l. 
[2
01
2]
66
62
51
≥6
 m
on
th
s
(i)
 M
ale
s, 
19
54
–2
00
8; 
(ii
) C
OP
D,
 SM
R,
 0.
63
 (9
5%
CI
, 0
.39
–0
.95
)
N
A
F—
Sa
th
ia
ku
m
ar
 e
t a
l. 
[1
99
8]
67
15
64
9
≥1
 y
ea
r
(i)
 M
ale
s, 
19
43
–1
99
1; 
(ii
) N
M
RD
, S
M
R,
 0.
71
, (9
5%
CI
, 0
.62
–0
.81
)
N
A
F—
 S
at
hi
ak
um
ar
 a
nd
 D
el
ze
ll 
[2
00
9]
68
48
63
≥1
 y
ea
r
(i)
 Fe
ma
les
, 1
94
3–
20
03
; (
ii)
 N
M
RD
, S
M
R,
 0.
97
, (9
5%
CI
, 0
.79
–1
.18
)
N
A
G
—
W
ei
la
nd
 e
t a
l. 
[1
99
6]
16
11
66
3
≥1
 y
ea
r
(i)
 M
ale
s, 
19
81
–1
99
1; 
ret
ire
d a
nd
 em
plo
ye
d 
w
o
rk
er
s;
 (i
i) 
NM
RD
, S
M
R,
 0.
97
 (9
5%
CI
, 0
.83
–1
.13
) 
(co
mb
ine
d),
 1.
03
 (9
5%
CI
, 0
.87
–1
.21
) (
ret
ire
d),
 an
d 0
.72
 (9
5%
CI
, 0
.46
–1
.08
) (
em
plo
ye
d) 
(ii
) C
OP
D,
 
SM
R,
 1
.1
5 
(95
%C
I, 0
.96
–1
.35
) (
co
mb
ine
d),
 1.
22
 (9
5%
CI
, 1
.01
–1
.46
) (
ret
ire
d),
 an
d 0
.85
 (9
5%
CI
, 0
.52
–
1.
31
) (
em
plo
ye
d)
+
+
G
—
St
ra
if 
et
 a
l. 
[2
00
0]
23
89
33
≥1
 y
ea
r
(i)
 M
ale
s, 
19
81
–1
99
1 (
ii)
 N
M
RD
, S
M
R,
 0.
99
 (9
5%
CI
, 0
.80
–1
.22
)
N
A
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C
oh
or
t a
nd
 re
fe
re
n
ce
N
o.
 o
f 
w
o
rk
er
s
R
eq
ui
re
d 
te
nu
re
Fi
nd
in
gs
St
re
n
gt
h 
of
 
ev
id
en
ce
a
G
—
V
la
an
de
re
n 
et
 a
l. 
[2
01
3]
17
13
39
5
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
81
–2
00
0 
(ii
) N
M
RD
, S
M
R,
 0.
97
 (9
5%
CI
, 0
.86
–1
.08
) (
ma
le)
 an
d 1
.13
 (9
5%
CI
, 
0.
65
–1
.8
3) 
(fe
ma
le)
+
H
—
W
in
gr
en
 [2
00
6]
69
57
45
>
1 
m
on
th
(i)
 M
ale
s, 
19
58
–2
00
1; 
(ii
) N
M
RD
, S
M
R,
 2.
06
, (9
5%
CI
, 1
.36
–3
.00
) (
< 6
 m
on
ths
 te
nu
re)
, 1
.92
 (9
5%
CI
, 
1.
23
–2
.8
5) 
(6 
mo
nth
s—
2.5
 ye
ars
 te
nu
re)
, 1
.23
 (9
5%
 C
I, 0
.71
–1
.96
) (
>2
.5–
10
 ye
ars
 te
nu
re)
, 0
.59
 
(95
%C
I, 0
.27
–1
.12
) (
>1
0 y
ea
rs 
ten
ure
), a
nd
 1.
46
 (9
5%
CI
, 1
.15
–1
.83
) (
10
 ye
ars
 la
ten
cy
); 
(ii
i) 
pn
eu
m
on
ia
b ,
 
SM
R,
 1
.2
3 
(95
%C
I, 0
.83
–1
.75
) (
10
 ye
ars
 la
ten
cy
); 
(iv
) c
hro
nic
 ai
rw
ay
 o
bs
tru
ct
io
n,
 S
M
R,
 
1.
67
 (9
5%
CI
, 1
.17
–2
.31
) (
10
 ye
ars
 la
ten
cy
)
+
+
I—
D
el
ze
ll 
et
 a
l. 
[1
98
1]
70
17
92
≥2
 y
ea
rs
(i)
 M
ale
s, 
19
54
–1
97
6; 
(ii
) N
M
RD
, S
M
R,
 0.
94
 (9
5%
CI
, 0
.51
–1
.57
)
N
A
J—
Bo
ni
ol
 e
t a
l. 
[2
01
6]
71
38
45
7
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
w
o
rk
in
g 
sin
ce
 1
97
5;
 (i
i) 
Re
sp
ira
tor
y d
ise
ase
s e
x
cl
ud
in
g 
pn
eu
m
on
ia
, S
M
R,
 0
.9
3 
(95
%C
I, 0
.72
–1
.19
) (
ma
le)
, 0
.74
 (9
5%
CI
, 0
.38
–1
.42
) (
fem
ale
), a
nd
 0.
90
 (9
5%
CI
, 0
.71
–1
.13
) 
(co
mb
ine
d)
N
A
K
—
 M
ira
be
lli
 e
t a
l. 
[2
01
2]
72
95
01
O
bs
er
va
tio
n 
sta
rte
d 
at
 th
e 
da
te
 o
f h
ire
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
62
–2
00
0;
 (i
i) 
NM
RD
, S
M
R,
 0.
67
 (9
5%
CI
, 0
.41
–1
.02
) (
ma
le)
N
A
L—
 G
us
ta
v
ss
o
n
 e
t a
l. 
[1
98
6]
73
87
34
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
52
–1
98
1;
 (i
i) 
NM
RD
, S
M
R,
 1.
15
 (9
5%
CI
, 0
.79
–1
.60
) (
ma
le)
; (
iii)
 as
thm
a, 
br
on
ch
iti
s, 
an
d 
em
ph
ys
em
a,
 S
M
R,
 1
.2
6 
(95
%C
I, 0
.72
–2
.04
) (
ma
le)
+
M
—
 T
ae
ge
r e
t a
l. 
[2
00
7]
74
95
97
≥1
 y
ea
r
(i)
 To
ta
l e
m
pl
oy
ee
s, 
19
81
–2
00
0;
 (i
i) 
NM
RD
, S
M
R,
 1.
06
 (9
5%
CI
, 0
.22
–3
.11
) (
ma
le)
; (
ii)
 C
OP
D,
 SM
R,
 
1.
37
 (9
5%
CI
, 0
.17
–4
.93
) (
ma
le)
+
N
—
 F
o
x
 e
t a
l. 
[1
97
4]
75
40
86
7
≥1
 y
ea
r
(i)
 M
ale
s, 
19
68
–1
97
1; 
(ii
) N
M
RD
, S
M
R,
 0.
84
 (9
5%
CI
, 0
.73
–0
.96
) (
all
 se
cto
rs)
 an
d 0
.55
 (9
5%
CI
, 0
.35
–
0.
80
) (
tir
e s
ec
tor
); 
(ii
) b
ron
ch
itis
, S
M
R,
 0.
86
 (9
5%
CI
, 0
.72
–1
.02
) (
all
 se
cto
rs)
 an
d b
ron
ch
itis
 an
d 
em
ph
ys
em
a,
 S
M
R,
 0
.8
2 
(95
%C
I, 0
.60
–1
.09
) (
tir
e s
ec
tor
)
N
A
N
—
Fo
x
 a
n
d 
co
lli
er
.
 
[1
97
6]
76
40
86
7
≥1
 y
ea
r
(i)
 M
ale
s, 
19
72
–1
97
4; 
(ii
) N
M
RD
, S
M
R,
 1.
02
 (9
5%
CI
, 0
.89
–1
.15
) (
all
 se
cto
rs)
 an
d 1
.51
 (9
5%
CI
, 0
.98
–
2.
23
) (
sec
tor
: s
po
ng
e r
ub
be
r, r
u
bb
er
 w
ith
 p
la
sti
c,
 c
re
pe
 ru
bb
er
,
 
et
c) 
(ii
) b
ron
ch
itis
, S
M
R,
 1.
14
 (9
5%
CI
, 
0.
96
–1
.3
4) 
(al
l s
ec
tor
s) 
an
d b
ron
ch
itis
, e
mp
hy
se
m
a,
 a
nd
 a
sth
m
a,
 S
M
R,
 1
.8
2 
(95
%C
I, 1
.06
–2
.94
) (
sec
tor
: 
sp
on
ge
 ru
bb
er
,
 
ru
bb
er
 w
ith
 p
la
sti
c,
 c
re
pe
 ru
bb
er
,
 
et
c)
+
+
CI
, c
on
fid
en
ce
 in
te
rv
al
; C
O
PD
, c
hr
on
ic
 o
bs
tru
ct
iv
e 
pu
lm
on
ar
y 
di
se
as
e;
 N
A
, n
o 
as
so
ci
at
io
n;
 N
M
RD
, n
on
-m
al
ig
na
nt
 re
sp
ira
to
ry
 d
ise
as
es
; S
M
R,
 st
an
da
rd
iz
ed
 m
or
ta
lit
y 
ra
tio
.
a S
tre
ng
th
 o
f e
v
id
en
ce
 fo
r p
os
iti
v
e 
as
so
ci
at
io
n:
 +
++
, s
tro
ng
; +
+,
 in
te
rm
ed
ia
te
; +
, n
on
-s
ig
ni
fic
an
t p
os
iti
v
e 
as
so
ci
at
io
n;
 d
ef
in
iti
on
s l
oc
at
ed
 in
 T
ab
le
 1
.
b S
M
R 
fo
r p
ne
um
on
ia
 in
cl
ud
es
 d
ea
th
s f
ro
m
 in
flu
en
za
 a
s w
el
l.
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